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Abstract  
Ergothioneine (EGT) is a naturally occurring sulphur-containing modified amino acid 
which has been shown to exhibit anti-oxidant properties. EGT is produced by selected fungi 
and prokaryotes, however Saccharomyces cerevisiae does not naturally produce EGT. Up to 
5 genes are involved in bacterial EGT biosynthesis while in fungi, two genes have been 
identified to be involved in EGT biosynthesis, and one such gene is egtA from Aspergillus 
fumigatus. Here, it is shown that expression of EgtA alone in the GRAS organism 
Saccharomyces cerevisiae facilities the production of EGT. The novel production of EGT in 
S. cerevisiae was confirmed by both HPLC and LC-MS analysis, and quantification of 
resultant EGT revealed a significantly (P < 0.0001) larger quantity of EGT present 
extracellularly in culture supernatants and accumulated therein until the time point of 96 h 
was reached. To complete the EGT biosynthetic process, a cysteine desulfurase is required, 
and two candidates were identified in A. fumigatus, namely AFUA_2G13295 and 
AFUA_3G14240, termed egt2a and egt2b in this study. Co-expression of egtA and egt2a in 
S. cerevisiae using high expression 2µ vectors was expected to increase EGT production, 
however EGT levels were seen to be significantly decreased (P < 0.05). As expression of egtA 
alone in S. cerevisiae been shown to effect EGT biosynthesis this raised the question of the 
ability of S. cerevisiae to complete the EGT biosynthetic process. A putative endogenous 
cysteine desulfurase Nfs1 was identified in S. cerevisiae. Interestingly decreasing the 
expression of Nfs1 was shown to increase levels of EGT. Moreover, manipulation of the 
conserved residue Thr213 in EgtA indicates indiscriminate phosphorylation by threonine 
kinases could be negatively regulating EGT production in S. cerevisiae. This study 
demonstrates quite remarkably that S. cerevisiae can produce EGT with the expression of just 
one additional protein. Hence, production of EGT using a synthetic biology approach now 
opens the possibility to economically viable means of producing EGT.
1 
 
 
 
 
 
 
 
 
 
Chapter 1 Introduction 
Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
1.1 The Aspergilli  
 
The Aspergilli are a diverse genus of over 250 different species of filamentous fungi 
known for the production of a wide array of natural products (NPs). NPs also referred to as 
secondary metabolites as their role is believed not to be crucial to the biochemical mechanisms 
that underpin the survival or the organism. Some members of Aspergillus have long held 
commercial applications such as A. oryzae used in the production of East Asian food products 
such as sake. Others like A. flavus are known for their economic and human cost infecting 
crops such as corn and peanuts which then go on to infect grain fed livestock ( Payne et al., 
1993). Because of this Aspergilli are thought of as both friends and foes through their role in 
producing high value food products and important NPs as well there economic and human 
cost through food spoilage and being an opportunistic pathogen. A key example of this is A. 
terreus an opportunistic human pathogen but is also the main source of the anticholesterol 
drug lovastatin with worldwide sales topping $10 billion annually (Kennedy et al., 1999). The 
potential discovery of NPs from fungi such as the aspergilli for anti-cancer drugs, 
nutraceuticals and antibiotics now has the possibility of growing with the genome sequencing 
of several key species such as A. fumigatus, A. oryzae, A. niger and A. nidulans (Nierman et 
al., 2005; Galagan et al., 2005; Machida et al., 2005; Pel et al., 2007).  As well as this over 
266 gene clusters have been identified producing known and unknown NPs from A. nidulans, 
A. oryzae, A. niger and A. fumigatus alone (Inglis et al., 2013).  
1.2. Aspergillus fumigatus 
 
Aspergillus fumigatus is a saprophytic fungus that is ubiquitous in the environment, 
playing an essential role in the carbon and nitrogen cycle colonising decaying organic matter 
and soil environments. A. fumigatus is one of 20 species in the genus Aspergillus known most 
for its pathogenicity constituting 90% of all invasive aspergillosis infections (Geiser et al., 
2007). A. fumigatus grows as a mass of septate fungal hyphae which produce asexual spores 
known as conidia which are commonly found in indoor and outdoor air at a concentration of 
1 to 100 per cubic metre (Sullivan et al., 2011). Conidia (only 2-3µm in diameter) are 
routinely inhaled by humans and penetrate deep into the lungs where they are typically 
destroyed by alveolar macrophages (Latgé, 2001). In immunocompromised patients or those 
with an underlying lung condition conidia are not killed by the host’s immune system which 
3 
 
can then cause a variety of respiratory infections. The three most common being allergic 
broncho-pulmonary aspergillosis, aspergilloma and invasive aspergillosis (Daly, 2001; 
Thompson & Patterson, 2008; Agarwal, 2009).  
Allergic broncho-pulmonary aspergillosis is an immunologic pulmonary disorder 
caused by hypersensitivity to A. fumigatus which manifests in non-immune compromised 
individuals with either severe asthma or cystic fibrosis (Agarwal, 2009; Greenberger, 2002; 
Tillie-Leblond & Tonnel, 2005). Aspergilloma is another infection caused by A. fumigatus 
which is the formation of a fungal ball in the upper respiratory tract and a sign of chronic 
cavity pulmonary aspergillosis. Infected individuals have a damaged respiratory tract usually 
from tuberculosis or sarcoidosis, which results in significant morbidity with severe cases 
requiring surgical intervention. The infection will develop over an extended period lasting 
months to even years (Tillie-Leblond & Tonnel, 2005; Pendleton & Denning, 2012; Howard 
et al., 2013). Invasive aspergillosis is the most common form of infection by A. fumigatus 
with a 40-90% mortality rate in high risk patient groups traditionally infecting neutropenic 
individuals such as HIV patients (Sullivan et al., 2011; Keeffe & Doyle, 2011). It has also 
been seen to infect individuals post organ transplant and haematopoietic stem cell recipients 
who recieve immunosuppressive drugs as well as those with an underlying condition such as 
leukaemia (Patterson et al., 2000; Marr et al., 2002). One feature which increases the 
virulence of A. fumigatus is its production of NPs which will be discussed in the next Section. 
1.3 A. fumigatus genome a reservoir of natural Products  
 
The genome of the A. fumigatus strain AF293 was first sequenced in 2005 and 
predicted to possess a total of 9,926 genes in 8 chromosomes totalling 29.4 Mb (Nierman et 
al., 2005).  This has led to the identification of 323 A. fumigatus genes involved in 
thermotolerance as well as more than 500 putative A. fumigatus specific genes with no 
identified homologues in A. nidulans or A. oryzae (Nierman et al., 2005). With the sequencing 
of the A. fumigatus strain AF293 genome mining for NP genes now uses many bioinformatics 
based tools to identify genes by their repetitive genomic patterns and unique domains (Ziemert 
et al., 2012). The Secondary Metabolite Unknown Region Finder (SMURF; 
www.jcvi.org/smurf), is a web based tool for the identification of NPs based on their genomic 
context and domain content (Khaldi et al., 2010). Another web based tool the antibiotics and 
Secondary Metabolite Analysis Shell (antiSMASH), locates novel NP genes using 
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biosynthetic loci from all of the known secondary metabolite classes (Medema et al., 2011). 
Use of such bioinformatic tools has led to the identification of many NP genes, which unlike 
those encoding for the transformation or biosynthesis of primary fungal metabolites tend to 
be located in clusters making them easier to locate (Khaldi et al., 2010).  However many genes 
that encode NPs may not express under laboratory conditions leaving many gene products  
unknown (Brakhage & Schroeckh, 2011).  
 .A. fumigatus when in the wild grows in highly competitive conditions, competing for 
space and nutrients. This has conferred selective pressures for the production of a wide array 
of NPs for better defence against other microorganisms, to increase the availability of 
nutrients and space for growth (Knox & Keller, 2015). NPs produced by A. fumigatus have a 
diverse range of beneficial applications such as anti-cancer, antimicrobial and others which 
aid in understanding the virulence of this organism (Wu et al., 2007; Sanchez et al., 2012).  
NPs such as siderophores are produced in iron limiting conditions and sequester iron 
from the surrounding environment. A. fumigatus produces a number of different siderophores 
of the hydroxamate type named by the three hydroxamate bidentate ligand system that 
chelates the Fe3+ ion (Hofte, 1993; Saha et al., 2013). Hydroxamate siderophores produced 
by A. fumigatus include fusarinine C an extracellular siderophore secreted by A. fumigatus 
which scavenges for iron in the environment and ferricrocin an intracellular siderophore used 
for iron storage (Barton & Hemming, 1993; Saha et al., 2013). A. fumigatus has been shown 
to have several mechanisms for regulating siderophores depending on the availability of iron 
and siderophores have been shown to be key to virulence in mouse models of invasive 
aspergillosis (Haas et al., 2008; Qin et al., 2009;  Schrettl et al., 2007).  
A significant contributing factor to the virulence of A. fumigatus is its production of 
harmful NPs such as helvolvic acid, fumigillin and the well characterised gliotoxin (Figure 
1.1). These toxins have been shown to damage human respiratory epithelium and slow the 
ciliary beat frequency (a key airways defence mechanism) in vivo (Delmotte & Sanderson 
2006; Amitani et al., 1995). However the diversity of NPs produced by A. fumigatus has 
shown to have a range of beneficial properties. Helvolvic acid,  long identified as having 
antimicrobial properties has been shown to enhance the killing of multi-drug resistant 
Staphylococcus aureus (MRSA) when combined with antibiotics such as erythromycin (Qin 
et al., 2009). Fumagillin is an antimicrobial agent and is an effective treatment of 
microsporidial infection in patients with HIV (Zbidah et al., 2013). Fumagillin has also been 
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shown to inhibit tumour induced angiogenesis in vivo and primary effusion lymphoma cell 
lines as well as lead to the development of fumagillin analogues with enhanced anti-tumour 
properties with less side effects (Zbidah et al., 2013; Kanno et al 2015; Ingber et al. 1990).   
 
 
                 
Figure 1.1 Natural products produced by Aspergillus fumigatus. The structures of 
helvolvic acid (A), fumagillin (B) and gliotoxin (C). Adapted from (Lee et al., 2008; Zhang 
et al., 2006; Davis et al., 2011) 
 
 
The fumitremorgins are a large group of prenylated indole alkaloid NPs produced by 
A. fumigatus containing either indole or indoline and isoprenoid moieties as well as their 
derivatives (Li, 2011). Derived from brevianamide F which consists of L-tryptophan and L-
proline they have a diverse range of biochemical activities. Fumitremorgins A, B as well as 
verruculogen were identified as tremorgenic mycotoxins. However, others such as 
tryprostatin and fumitremorgin C have been seen to reverse the resistance of some tumour 
cell lines against antitumor agents (González-Lobato et al., 2010; Wu et al., 2007). 
Tryprostatin and fumitremorgin C were noted to be specific inhibitors of the breast cancer 
resistance protein ABCG2, an ATP-binding cassette transporter which efflux’s 
A 
C 
B 
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chemotherapeutic compounds out of tumour cells (Li, 2011; Rabindran et al., 2000; Staud & 
Pavek, 2005). Naturally occurring thiol NPs are required by microbes and Mammalia alike to 
detoxify harmful molecules and will be discussed in the following Section. 
1.4 Production of thiol natural products by Microbes 
 
Thiols are present in living systems and carry out essential cellular roles such as 
maintenance of cellular redox homeostasis, protein thiol disulphide ratios and protection from 
reactive oxygen species (ROS) (Hand & Honek, 2005).  Glutathione (GSH) (Figure 1.2), is a 
well-known antioxidant produced by bacteria, fungi and Mammalia alike. In Mammalia it has 
been identified to be involved in the regulation of cell proliferation, apoptosis, immune 
function, and fibrogenesis (Lu, 2013). GSH is a γ-glutamyl-cysteinyl-glycine tripeptide it acts 
as a radical scavenger of ROS and xenobiotics which cause oxidative damage to proteins and 
macromolecules (Schafer & Buettner, 2001). GSH has also been shown to reduce unwanted 
protein disulphide formations created by the presence of ROS (Berndt et al., 2008). GSH 
exists in the thiol reduced form at physiological pH when it is most reactive until becoming 
oxidised to its disulphide form (GSSG) (Kaplowitz et al., 1985). The antioxidant function of 
GSH is largely accomplished by GSH peroxidase which catalyses the reduction of ROS such 
as hydrogen peroxide and lipid peroxide while GSH is oxidised. Disulphide GSH is then 
reduced back to GSH by GSH reductase (Lu, 2013).  
 
Figure 1.2 The structure of Glutathione. In its thiol form GSH is highly unstable and is 
easily oxidised to its disulphide form. Adapted from Schafer & Buettner, 2001. 
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Protozoa such as the Trypanosoma produce a unique thiol to deal with ROS. 
Trypanosoma such as Trypanosoma brucei which cause over 66,000 deaths annually produce 
trypanothione as well as GSH to dissipate ROS (Fairlamb et al., 1985). Certain bacteria do 
not utilize GSH for redox homeostasis and use other thiols instead such as mycothiol (MSH) 
(Figure 1.3), used by Mycobacteria and Streptomyces species (Hand & Honek, 2005). MSH 
has a wide range of roles as well as deactivating free radicals it also mediates antibiotic 
resistance as demonstrated in Mycobacterium smegmatis  (Rawat et al., 2002). MSH is also 
required in the synthesis of the antibiotic lincomycin in Streptomyces lincolnensis (Zhao et 
al., 2015). However Mycobacteria such as Mycobacterium smegmatis produce other NPs to 
help eliminate ROS. This indicates that GSH alone may not be enough for an organism to 
maintain their redox homeostasis and requires a variety thiol NPs to manage their redox 
homeostasis. One such NP is ergothioneine (EGT) which will be discussed more in the 
following Sections. 
 
        
Figure 1.3 The structure of mycothiol. Detoxification of ROS is mediated through its 
reactive thiol group. Adapted from (Fahey, 2001). 
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1.5 Ergothioneine 
 
 EGT is a low molecular mass thiol metabolite produced by various bacteria and non-
yeast fungi and has been observed to have antioxidant properties. First identified by Tanret in 
1909 in the ergot fungus Claviceps purpurea EGT has now been identified to be produced 
across the bacterial and fungal kingdoms in model organism such as A. fumigatus and M. 
smegmatis (Tanret, 1909). Plants and animals do not synthesize EGT but acquire it through 
dietary means. Plants acquire EGT through their roots or via microbial symbionts (Park et al., 
2010). Animals acquire EGT from food including mushrooms, oats, beans and red meat which 
are all rich sources of EGT (Ey et al., 2007).  
EGT is a betaine derivative of the proteinogenic amino acid histidine with a thiol 
group located on the C2 atom of the imidazole ring (Halliwell & Gutteridge, 2007). EGT is 
tautomeric (Figure 1.4) and has a higher redox potential of -0.06 V compared to other 
naturally occurring thiols which have a typical range between -0.2 V and -0.32 V. This confers 
greater stability to EGT under physiological conditions preventing EGT from undergoing auto 
oxidation as rapidly as other thiols such as GSH which predominately exists as a thiol (Cheah 
& Halliwell, 2012). 
 
 
Figure 1.4 Ergothioneine in its thiol and thione form. (A) Ergothioneine in its thiol form 
attached to the imidazole ring by a single bond. (B) Ergothioneine in its thione form attached 
to the imidazole ring by a double bond. Adapted from Fahey, (2001). 
 
A B 
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EGT, because it is predominately in its thione form at physiological pH is highly stable 
(Hand et al., 2005). One study demonstrated how rats fasted for 1 week showed no drop in 
the level of EGT in blood or liver (Mayumi et al., 1978).  In humans EGT accumulates in 
cells at a concentration between 100 µM and 2 mM and is most abundant in bone marrow, 
kidney, seminal fluid and the lens and cornea of the eyes (Shires et al., 1997). The putative 
transporter protein formally known as organic cation transporter 1 (OCTN1) encoded by the 
gene SLC22A4 has been identified as having high affinity for EGT (Nikodemus et al., 2011).  
OCTN1 now identified as an EGT transporter (ETT) actively retains EGT inside the cell 
(Nikodemus et al., 2011). EGT exhibits antioxidant activity and has been identified as a 
cytoprotectant inside mammalian cells potentially representing a new vitamin (Paul & Snyder, 
2009).  
1.6 Biosynthetic pathways of ergothioneine 
 
 EGT has a molecular mass of 229.3 and a high solubility in aqueous solutions of 0.9 
M at 25 °C (Halliwell & Gutteridge, 2007). Naturally occurring EGT is in the L- 
configuration, synthesized from L-Histidine always and followed by either γ-glu-cys or L-
cysteine depending on what biosynthetic pathway is used (Seebeck, 2010; Bello et al., 2012). 
A variation in the biosynthetic pathway occurs in bacteria and fungi through instances of a 
gene fusion event causing a change of substrates used in the pathway (Figure 1.5).  
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Figure 1.5 The ergothioneine biosynthetic pathways in M. smegmatis and N. crassa. Note 
how only 2 enzymes are required by N. crassa to synthesize EGT unlike M. smegmatis which 
requires 5 including EGTA to produce the substrate γ-glu-cys. EGT-1 like EGTD acts as a 
methyl transferase using the universal methyl donor SAM. However, when catalysing the C-
S bond EGT-1 uses cysteine instead of γ-glu-cys as a substrate producing one less 
intermediate γ-glutamyl hercynyl sulfoxide. Both EGT-2 and EGTE carry out the same 
function as a desulfurase cleaving the C-S bond leaving the sulphur attached to C2 on the 
imidazole ring. Adapted from Pluskal et al., 2014. 
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In mycobacteria such as Mycobacterium smegmatis and Mycobacterium tuberculosis 
a 5 gene cluster (egtA, egtB, egtC, egtD and egtE) is responsible for the biosynthesis of EGT 
(Seebeck, 2010; Emani et al., 2013; Saini et al., 2015).  EgtD identified by Seebeck (2010), 
as a methyltransferase transfers 3 methyl groups onto L-histidine using S-adenosyl 
methionine (SAM) as a cofactor forming hercynine the first step in EGT biosynthesis 
(Seebeck, 2010; Vit et al., 2014). EgtA was identified as a γ-glutamylcysteine ligase 
suggesting γ-glu-cys was the sulphur donor rather than cysteine. EgtB a sulfoxide synthase 
catalyses the formation of a C-S bond in an O2 dependant manner using hercynine and γ-glu-
cys as ligands in an octahedral iron binding site (Goncharenko et al., 2015). Fe(II) is required 
as a cofactor to initiate the catalytic mechanism for C-S bond formation by an iron(III)-
complexed thiyl (Goncharenko et al., 2015; Seebeck, 2010). FeSO4 acts as the iron cofactor 
for the iron(III)-complexed thiyl radical which attacks the imidazole ring of hercynine 
catalysed by EgtB using hercynyl and γ-glu-cys  as substrates to produce S-hercynyl-γ-
glutamylcysteine (Goncharenko et al., 2015). EgtC a glutamine amidohydrolase removes the 
γ-glutamyl tail generating hercynylcysteine sulfoxide (Vit et al., 2015). The final step is 
carried out by EgtE a pyridoxal-5-phosphate-dependent ß-lyase which cleaves the cysteine 
residue causing a net transfer of the sulphur atom from cysteine to histidine forming EGT 
(Seebeck, 2010; Song et al., 2015).   
 The Neurospora crassa egt-1 (Ncegt-1) was the first fungal EGT biosynthetic 
gene identified by Bello et al in Neurospora crassa. Ncegt-1 was identified as a fusion protein 
of EgtD and EgtB containing a SAM dependant methyltransferase domain as well as a 
sulfoxide synthase domain (Bello et al., 2012). This fusion event is not restricted to fungal 
species, Jones et al observed 2 independent instances with 5 species of the α-protobacteria 
order having a fusion protein of egtB and egtD (Jones et al., 2014). The Egt-1 fusion protein 
is still more common in fungi with 73 Egt-1 orthologues identified based on NcEgt-1 however 
all Saccharomycotina species are missing Egt-1 (Bello et al., 2012; Jones et al., 2014). It is 
interesting that many species that produce ergothioneine do not have orthologues to the genes 
egtA, egtC or egtE suggesting they are not as crucial as EgtB and EgtD (Jones et al., 2014; 
Pfeiffer et al., 2011). Further evidence from M. tuberculosis has shown how egtB and egtD 
are expressed in tandem unlike EgtA, EgtC or EgtE suggesting other enzymes may play a role 
in completing the biosynthesis of EGT (Jones et al., 2014).  
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1.7 Ergothioneine redox activity and potential uses 
 
In vitro EGT is known to be a powerful scavenger of hydroxyl radicals (OH), 
hypochlorous acid (HOCL), and peroxynitrite (ONOO-) (Whiteman & Halliwell 1997), 
(Franzoni et al., 2006). EGT was also shown to deactivate singlet oxygen at a higher rate than 
other simple thiols including GSH (Rougee et al., 1988). In vitro EGT has been demonstrated 
to chelate divalent metal ions and to form complexes with Cu2+, Hg2+, Zn2+, Cd2+, Co2+, Fe2+, 
and Ni2+ (Hanlon, 1971;  Motohashi et al., 1974). A molar ratio of 2:1 is formed with metal 
ions the most stable being Cu2+ (Motohashi et al., 1974). This was taken one step further by 
Zhu et al who identified EGT as protecting DNA and protein against damage induced by Cu2+, 
hydrogen peroxide and ascorbate by forming a redox inactive EGT-Cu complex in vitro (Zhu 
et al., 2011). This is unlike GSH which has been shown to generate superoxide anions when 
in a Cu(I)-GSH complex (Speisky et al., 2008). However in vivo studies have shown EGT not 
to be involved in sequestering Cu2+ (Bello et al., 2012).  
EGT is noted to be highly stable especially at physiological pH, a contributing factor 
of this is its unique oxidation. Servillo et al., (2015) demonstrated that EGT in the presence 
of either hypochlorite, peroxynitrite or hydrogen peroxide were shown to produce the 
products EGT disulphide, EGT sulfonic acid and hercynine in vitro (Figure 1.6). Further 
analysis showed that EGT disulphide decomposed into EGT sulfenic acid and EGT with 
ESOH as well breaking down into EGT and ESO2H (Figure 1.7), (Servillo et al., 2015). This 
perhaps helps explain how even a low EGT diet causes its accumulation in tissues and to 
remain there for a considerable length of time compared to other thiols such as GSH (Halliwell 
et al., 2016).  
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Figure 1.6 A-C Novel products of the oxidation of ergothioneine by the ROS 
hypochlorite, peroxynitrite and hydrogen peroxide. (A) Ergothioneine sulfonic acid 
(ESOH), (B) hercynine (EH) and (C) ergothioneine disulphide (ESSE). Adapted from 
(Servillo et al., 2015). 
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Figure 1.7 A-D Proposed decomposition of EGT. EGT reacts with ROS undergoing 
oxidation into ESSE which undergoes hydrolysis. Each 2 mol of ESSE disproportionates into 
2 mol of highly reactive ESOH and 2 mol of EGT. 2mol of ESOH disproportionates into 1 
mol of ESO2H and 1 mol of EGT. ESO2H then decomposes irreversibly into EH and H2SO2 
(Servillo et al., 2015). 
 
No functional role of EGT has been conclusively determined yet for EGT in 
mammalian tissue. EGT has demonstrated as having considerable antioxidant activity in vitro 
however its role in vivo is still unclear. One possible role may be as a cytoprotectant from 
ultraviolet (UV) light which damages skin by inducing ROS (Norins, 1962). Studies have 
shown EGT to protect against UV damage and absorb light in the UV range (Cheah & 
Halliwell, 2012).  The cytoprotective effect of EGT against UV damage of cells is well 
documented (Botta et al., 2008;  Pinnell et al., 2009). EGT has been shown to be of use in the 
food industry acting as a preservative to prevent discolouration of red meat and fish as well 
as inhibiting lipid peroxidation and melanin blackspot formation from phenoloxidase activity 
(Bao et al., 2010; Fedorova et al., 2008). 
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1.8 The ergothioneine transporter  
 
OCTN1 the EGT transporter (ETT) is a Na+ dependant membrane protein of the 
SLC22A4 transport protein family identified by Gründemann (2012). ETT has a highly 
conserved amino acid sequence between orthologues such as rat with 85.5 % similarity 
(Gründemann, 2012). Its 3D structure has not yet been elucidated but from hydropathy plot 
analysis it has a large extracellular loop with multiple potential N-glycosylation sites between 
its transmembrane regions 1 and 2 with multiple potential phosphorylation sites 
(Gründemann, 2012). ETT has a very high specificity for EGT compared to other similar 
compounds such as hercynine and carnitine with a 25 and 100 fold lower transport rate 
respectively (Cheah & Halliwell, 2012 ;Gründemann et al., 2005). High expression of ETT is 
directly linked to the accumulation of high quantities of EGT intracellularly as EGT is 
prevented from crossing the cell membrane due to it being a hydrophilic zwitterion(Gruber et 
al., 2013). Because of this expression of ETT gives insight into EGT activity due to the 
selectivity of ETT for EGT. Cells such as developing red blood cells, seminal vesicles all 
express ETT highly and have been shown to contain EGT at high levels (Nikodemus et al., 
2011; Paul & Snyder, 2009).  
ETTs main site of localisation is the plasma membrane and reportedly at the 
mitochondria but this is not yet clear. Lamhonwah & Tein (2006) identified the majority of 
ETT in the membrane of mitochondria using a GFP fusion protein of human ETT at the N-
terminus. However it was argued by Gründemann (2012), that this study was invalid as the 
fusion construct lacked 34 original amino acids of the N-terminus including 13 out of the 21 
amino acids in the transmembrane segment 1 and had an additional 36 non-natural amino 
acids. This was supported by Bacher et al., (2009) who showed that GFP attached to the C 
terminus of human ETT with the original amino acid structure was located in the plasma 
membrane only. Contrary to this Kawano et al., (1982) in a study demonstrated  that 
radiolabelled EGT fed to rats accumulated most in the mitochondria. Paul & Snyder (2009) 
in a comprehensive in vivo study silenced ETT expression in HeLa cells using RNAi 
knockdown. They demonstrated how HeLa cells no longer expressing ETT had a higher 
degree of mitochondrial DNA (mtDNA) damage than cells which still had ETT after cells 
were supplemented with EGT and stressed with hydrogen peroxide. From such studies 
evidence suggests ETT is expressed on the mitochondrial membrane as well as the plasma 
membrane of cells and may have an antioxidant role in the mitochondria protecting mtDNA 
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however more in vivo studies need to be undertaken (Kawano et al., 1982; Lamhonwah & 
Tein, 2006; Paul & Snyder, 2009). 
 
1.9 Conditions associated with ergothioneine  
 
1.9.1 The role of ergothioneine in inflammatory diseases 
 
The transcription factor NF-κß which regulates inflammatory genes has binding sites 
in the promoter of human ETT and actively regulates its expression (Maeda et al., 2007). ETT 
expression has also seen to be upregulated by inflammatory cytokines (Tokuhiro et al. 2003; 
Peltekova et al., 2004; Taubert et al., 2009; Rahman et al., 2003; Maeda et al., 2007).  This 
accounts for a higher level of EGT in erythrocytes of rheumatoid arthritis sufferers as 
inflammatory cytokines are also upregulated (Taubert et al., 2006). With this in mind EGT 
could perhaps act as a biomarker in certain inflammatory diseases (Gründemann, 2012). ETT 
is also seen to be selectively expressed when needed during different developmental stages 
such as being highly expressed in foetal liver and during liver regeneration but not in adult 
liver (Nakamura et al., 2007; Gründemann, 2012). 
ETT upregulation has been associated with auto-inflammatory diseases such as 
rheumatoid arthritis, ulcerative colitis, Crohns disease and neurodegenerative diseases such 
as Parkinson’s and Alzheimer’s disease (Maeda et al., 2007; Kato et al., 2010; Santiago et al., 
2006; Taubert et al., 2006). The ETT gene is in close proximity to genes involved in 
inflammatory responses such as the caspase recruitment domain family and CARD 15 (Bene 
et al., 2006). ETT is also highly expressed in CD14+ macrophages and monocytes both with 
a key inflammatory role (Paul & Snyder, 2009). Silencing of ETT in HeLa cells has shown 
cells pre-treated with 1 mM EGT have been significantly more resistant to hydrogen peroxide 
than HeLa cells deficient of ETT with a distinct correlation between ETT depletion and 
apoptosis (Paul & Snyder, 2009). EGT has also been shown to inhibit the release of the pro-
inflammatory cytokine IL-8 by inhibiting there release from TNF-α in alveolar macrophages 
(Rahman et al., 2003). Patients with rheumatoid arthritis have high levels of EGT in there 
synoviocytes (Nakamura et al., 2007).  
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1.9.2 The role of ergothioneine in Crohns Disease 
 
 Polymorphisms in the ETT gene SLC22A4 have been attributed to several diseases 
and the information is as of yet inconclusive. European patients with Crohns disease CD have 
been identified as having significantly lower blood levels of EGT in their blood as well as a 
high risk haplotype identified by single nucleotide polymorphisms present at the IBD5 locus 
in SLC22A4 (Kato et al., 2010), . These mutations are L503F and G207C, with L503F being 
of great interest due to it increasing the ETT intrinsic transport efficiency by 50% compared 
with the non-risk variant 503L (Taubert et al., 2009). However a study by Fisher et al., (2006) 
concluded the frequencies of individuals who did not carry the general IBD5 risk haplotype 
was not significantly different in cases and controls. A study of Japanese CD sufferers also 
came to the conclusion the mutations L503F and G-207C attributed with disease pathology in 
Caucasian CD patients were not present at all in any of the patients tested (Kato et al., 2010). 
This indicates these mutations may not be involved in disease etiology and could perhaps be 
used as a genetic marker for CD in European patients. Patients with CD have been identified 
as having significantly lower levels in their blood indicating that perhaps EGT is undergoing 
oxidation (Kato et al., 2010).  
1.9.3 Ergothioneine protects against Neurodegeneration 
 
EGT has been identified in mammalian cells at a concentration between 1 and 2 mM 
and is able to permeate the blood brain barrier (Yang et al., 2012). EGT is detected in sheep, 
rat, guinea pig, rabbit, cat and mouse brains between 0.3 and 1 mg per 100 g of brain tissue 
(Briggs, 1972; Crossland et al., 1966; Kaneko et al., 1980).  EGT exhibits a protective role 
against neurodegeneration in vitro and in vivo. Rat pheochromocytoma cells (PC12) are a 
common model for neurobiological studies possessing neuron like features such as neurite 
formation and terminal differentiation in response to growth factors as well as expressing 
ETT. Cisplatin is an anti-tumour agent that has nephrotoxic and neurotoxic side effects when 
administered during chemotherapy. When cisplatin is incubated with PC12 cells a marked 
decrease in PC12 proliferation as well as strong inhibition of axon and dendrite growth was 
observed. When PC12 cells were incubated with EGT prior to incubation with cisplatin the 
effects of cisplatin were significantly inhibited (Song et al., 2010). An in vivo study also 
demonstrated how mice injected with cisplatin had increased learning and memory deficits 
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compared to mice injected with cisplatin and fed a high EGT diet which significantly restored 
learning and memory deficits (Song et al., 2010).  
EGT has been shown in vivo to protect against the ß-amyloid peptides which are 
neurotoxic and contribute to Alzheimer’s disease (Pike et al., 1991). Mice given a dose of ß-
amyloid directly into the hippocampus showed increased brain lipid peroxidation and 
acetylcholinesterase activity, significant decreases in GSH as well as significant decreases in 
superoxide dismutase activity of brain tissue (Yang et al., 2012). Groups fed a dose a low as 
0.5 EGT/ kg daily over two separate intervals before and after injection of ß-amyloid showed 
a significant decrease in brain lipid peroxidation and acetylcholinesterase activity, a 
significant decrease in the decline of GSH as well as significantly increasing the level of 
superoxide dismutase activity in brain tissue (Yang et al., 2012). 
1.9.4 The role of ergothioneine in Parkinsons disease 
 
As noted ETT is present on the membrane of mitochondria with high levels of EGT 
shown to accumulate there (Lamhonwah & Tein, 2006). MtDNA is uniquely susceptible to 
oxidative damage as unlike nuclear DNA mtDNA is not protected by histones and lacks 
efficient DNA repair mechanisms (Godley et al., 2005). Evidence suggests that mitochondria 
contribute to aging and cognitive decline by production of ROS which are produced as part 
of the electron transport chain of mitochondria (Gruber et al., 2013). ROS damages mtDNA 
causing point mutations which increase as the individual ages (Lin & Beal, 2006 ;Trifunovic 
et al., 2005). With the brain being a high energy organ ROS damage to mtDNA has been 
identified as being involved in neurodegenerative diseases such as Parkinson’s disease (PD) 
and Alzheimer’s disease (Lin & Beal, 2006). Clinical studies of patients with PD contain 
significantly lower levels of EGT as well as the antioxidant bilirubin in blood indicating 
elevated levels of oxidative stress (Hatano et al., 2015).  The reduced level of EGT correlated 
with disease severity and may have potential to use EGT as a biomarker in PD as well as a 
supplement to help maintain redox balance lost during PD. It has been argued that EGT now 
meets the requirement to be designated a vitamin as its deficiency has been shown to have 
several cytotoxic consequences in cell lines both in vivo and in vitro (Cheah & Halliwell, 
2012; Paul & Snyder, 2009; Rahman et al., 2003). EGT has been suggested as a dietary 
supplement to treat chronic obstructive pulmonary disease (Biswas et al., 2013). However as 
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of yet EGT deficiency on its own has not been shown to cause disease (Cheah & Halliwell, 
2012; Kawano et al., 1982; Kato et al., 2010).   
1.10 Ergothioneine in Bacteria and Fungi 
 
1.10.1 The role of ergothioneine in redox homeostasis, virulence and NP production in 
 Bacteria 
 
 Mycobacteria do not produce GSH the well-established antioxidant known for its 
efficient scavenging and detoxifying of ROS such as hydrogen peroxide (Lu, 2013) . Instead 
Mycobacteria produce low molecular mass thiols MSH and EGT (Van Laer et al., 2013). In 
M. tuberculosis MSH deficient mutants have been shown to have increased sensitivity to 
oxidative stress, alkylating agents as well as a range of antibiotics such as erythromycin, 
vancomycin and streptomycin (Saini et al., 2015). EGT has also been shown to play a role in 
redox balance which is essential for energy metabolism, such as glycolysis, the tricarboxylic 
cycle and oxidative phosphorylation (Saini et al., 2015). In M. tuberculosis EGT was 
identified to be regulated by the oxidative stress sensor and regulator of bioenergetics 
homeostasis WHIB3 (Saini et al., 2015). MSH and EGT have both been shown to be critical 
for bioenergetic redox homeostasis with a lack of either altering cellular respiration (Saini et 
al., 2015).  
Upregulation of EGT biosynthesis in Mycobacterium has also been identified in 
nutrient starved conditions by a decrease in phosphorylation of the methyltransferase EGTD 
on T-213. (Richard-Greenblatt et al., 2015). EGT has been identified as playing a role in the 
virulence of M. tuberculosis with EGT biosynthesis upregulated during the infection of mice 
and macrophages as well as required for long term infection (Saini et al., 2015; Richard-
Greenblatt et al., 2015). Additionally EGT in M. tuberculosis mediates resistance to 
antibiotics such as rifampicin and isoniazid (Saini et al., 2016). However studies using M. 
smegmatis which secretes EGT and have shown it to protect against peroxides but not increase 
susceptibility to antibiotics such as isoniazid, ethambutol and kanamycin in egtD deletion 
mutants  (Emani et al., 2013)  
For first time EGT has shown to be involved in enzymatic reactions involving the 
biosynthesis of the antibiotic lincomycin in Streptomyces lincolnensis. EGT was shown to be 
involved in a unique S-glycosylation step acting as a carrier of the lincomycin precursor 
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lincosamide and is removed by a unique thiol exchange with mycothiol which allows the 
recycling of EGT (Zhao et al., 2015). Cyanobacteria have also been seen to produce large 
quantities of EGT, and also produce GSH (Pfeiffer et al., 2011). Interestingly deletion of gshB 
in Cyanobacterium synechocystis which codes for a GSH synthase protein caused abolition 
of intracellular EGT production causing accumulation of the precursor hercynine 
(Narainsamy et al., 2015). This indicates a different EGT biosynthetic pathway dependant on 
GSH. 
1.10.2 The role of ergothioneine in redox homeostasis in Fungi 
 
In N. crassa in vivo EGT was shown to be one third the antioxidant capacity in conidia, 
protecting conidia against peroxide damage, but played no significant role in antioxidant 
stress in the mycelia (Bello et al., 2012; Bello et al., 2014). EGT involvement in protection 
of DNA was investigated with EGT having no effect on the rate of DNA mutation caused by 
UV light (Bello et al., 2014). In A. fumigatus deletion of the gliK gene involved in gliotoxin 
biosynthesis and mediation of oxidative stress caused a significant increase in the level of 
intracellular EGT indicating an attempt by the fungus to mediate resistance to increased 
oxidative stress (Gallagher et al., 2012). In the fission yeast Schizosaccharomyces pombe 
EGT production has been identified as well as the genes responsible egt-1 and egt-2. In 
overexpression or deletion mutants of egt-1 no increase in resistance or increased sensitivity 
to ROS was observed when mutants were exposed to hydrogen peroxide and tert-butyl 
hydroperoxide (Pluskal et al., 2014). Interestingly it was also shown that supplementation of 
media with sodium selenate allowed the synthesis of the selenium analogue to EGT 
selenoneine (Pluskal et al., 2014). Selenoneine has been shown be present in fish such as 
mackerel and tuna and to have antioxidant properties in vitro (Yamashita et al., 2013)This 
shows the flexibility of EGT-1 to bind to other substrates most likely selenocysteine as an 
alternative substrate to cysteine as hercynyl selenocysteine was also identified using 
metabolomic analysis (Pluskal et al., 2014).  
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1.11 The use of yeast in biotechnology  
 
Yeast are single celled eukaryotic organisms often used for producing recombinant 
proteins that are not well produced in bacteria such as E. coli because of problems with folding 
or glycosylation. They are easier and less expensive to work with than mammalian cells such 
as Chinese hamster ovary (CHO) cells (Demain & Vaishnav, 2009). Yeast is used to produce 
vaccines against tumour antigens such as vaccines generated against RAS antigens on RAS 
oncoproteins (Ardiani et al., 2010). It can also secrete protein into the supernatant with the 
proper signals and produce high levels of heterologous recombinant protein such as producing 
9 g/L of the enzyme glucose oxidase (Demain & Vaishnav, 2009).  
1.11.1 S. cerevisiae as a cell factory 
 
Saccharomyces cerevisiae was the first eukaryotic cell engineered to express 
heterologous proteins due to it possessing many favourable features such as rapid growth by 
cell division, having its own autonomously replicating plasmid, its formation of discrete 
colonies and ability to carry out post translational modifications of expressed proteins (Curran 
and Bugeja, 2011). S. cerevisiae has GRAS status having a long history of safe use in the 
commercial fermentation process and unlike Escherichia coli does not produce pyrogens and 
endotoxins (Rosales-Mendoza et al., 2015).  S. cerevisiae is excellent at producing 
recombinant proteins from other eukaryotic organisms and is used successfully to produce 
insulin and hepatitis B vaccine (Demain & Vaishnav, 2009). However S. cerevisiae mediated 
over glycosylation of N linked sites can cause reduced activity and immunological problems 
in the production of mammalian recombinant proteins (Demain & Vaishnav, 2009). Better 
engineering of strains and the development of protease-deficient strains will allow increased 
production of mammalian proteins such as interferon ß (Tomimoto et al., 2013; Zhang et al., 
2012) .  This makes S. cerevisiae an ideal for the expression of recombinant proteins.  
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1.12 Aims of Study 
 Characterisation and elucidation of the small molecule EGT has shown it may play a 
role as an antioxidant and cytoprotective in vivo. These interesting cellular roles make EGT a 
potential nutraceutical and perhaps capable of being utilized as a food additive. However no 
economically viable means of producing EGT has yet been established.  
To achieve this: 
 
1) The primary objective of this study is to biosynthetically produce the natural product 
EGT in the yeast S. cerevisiae by expression of recombinant EgtA from A. fumigatus, 
or with the co-expression of other foreign genes if required. 
 
2) Quantify how much EGT is being produced by the expression of recombinant proteins 
in S. cerevisiae and determine if EGT is inside the cell or in the culture supernatant. 
 
3) Investigate whether production of EGT by S. cerevisiae has any benefit to the 
organism such as alleviation of oxidative stress.  
 
4) Identify ways to increase the amount of EGT produced by S. cerevisiae through further 
genetic manipulation of EgtA and S. cerevisiae and in doing so gain a better 
understanding of how EGT is produced in S. cerevisiae  
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Chapter 2 Materials and Methods 
    Materials and Methods 
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2.1 Materials 
2.1.1 Strains in this study 
Table 2.1 S. cerevisiae and bacterial strains used 
Strain Genotype Source 
BY4741 MATa his3Δ 1; leu2Δ; met15Δ 0; ura3Δ 0 Euroscarf 
R1158 
MATa his3Δ 1; leu2Δ; met15Δ; 
pNFS1::kanR-tet07-TATA; ura3::CMV-
tTA 
Dharmacon 
R1158 MATa his3Δ 1; leu2Δ; met15Δ; 
pSAH1::kanR-tet07-TATA; ura3::CMV-
tTA 
Dharmacon 
Y258 MATa pep4-3; his4-580; ura3-52; leu2-3 Dharmacon 
 Top 10 E. coli This study 
 Xli-blue E. coli This study 
 
2.1.2 Plasmids used in this study 
Table 2.2 Plasmid vectors used in this study 
Plasmid name Description Source 
PUC57 E. coli expression vector  Genscript 
pRS316 Centromeric Saccharomyces cerevisiae 
shuttle vector- URA3 marker 
Sikorski and Hieter, 
1989 
pC210 SSA1 under control of SSA2 promoter- 
LEU2 marker 
Schwimmer and 
Masison, 2002 
p413-ADH Low copy centromeric plasmid with an 
ADH promoter based on the pRS vector 
series- HIS3 marker 
Mumberg, et al 1995 
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p413-GPD Low copy centromeric plasmid with a 
GPD promoter based on the pRS vector 
series- HIS3 marker 
Mumberg, et al 1995 
p416-ADH Low copy centromeric plasmid with an 
ADH promoter based on the pRS vector 
series- URA3 marker 
Mumberg, et al 1995 
p416-GPD Low copy centromeric plasmid with a 
GPD promoter based on the pRS vector 
series- URA3 marker 
Mumberg, et al 1995 
p423-ADH High copy 2µ plasmid with an ADH 
promoter based on the pRS vector series- 
HIS3 marker 
Mumberg, et al 1995 
p423-GPD High copy 2µ plasmid with a GPD 
promoter based on the pRS vector series- 
HIS3 marker 
Mumberg, et al 1995 
p426-ADH High copy 2µ plasmid with an ADH 
promoter based on the pRS vector series- 
URA3 marker 
Mumberg, et al 1995 
p426-GPD High copy 2µ plasmid with a GPD 
promoter based on the pRS vector series- 
URA3 marker 
Mumberg, et al 1995 
p426-GPD-egtA Aspergillus fumigatus egtA  under control 
of GDP promoter- URA3 marker 
This study 
P423-ADH-egta Aspergillus fumigatus egt2a  under control 
of ADH promoter- HIS3 marker 
This study 
P423-ADH-egt2b Aspergillus fumigatus egt2b under control 
of ADH promoter- HIS3 marker 
This study 
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2.1.3 Primers used in this study 
Table 2.3 Primer sequences used in this study 
Primer name Sequence (5’-3’) 
EgtA F AAATTTACTAGTATGTCCCCGTTGCCG 
EgtA R AATTCCCTCGAGCTACTGGCTGCGCACG 
EgtA Internal F AGAACCTACAGCGTCCCACTG 
EgtA Internal 
R 
CTTGACCTCCTCATAAGTGGG 
Egt-2a F AGATGCACTAGTATGTCCGCTCCCACA 
Egt-2a R AAGTCAGAATTCTCACAACTTTGGCTC 
Egt-2b F GGGCCCACTAGTATGTCTAGCGTTACGCCATCT 
 
Egt-2b R GGGCCCGAATTCCTAATGCTGACTCCATTGGAT 
 
EgtA N-
terminal His 
tag 
AGAACTAGTATGCATCATCACCACCACCATATGTCCCCGTTGCCGTGTCC 
Egt-2a N- 
terminal His 
tag 
GGGCCCACTAGTATGCATCATCACCACCACCATATGTCCGCTCCCACA 
 
Egt-2b N- 
terminal His 
tag 
GGGCCCACTAGTATGCATCATCACCACCACCATATGTCTAGCGTTACGCC
ATC 
 
Egt-2b C- 
terminal His 
tag 
GAGGAATTCCTAATGGTGGTGGTGATGATGATGCTGACTCCATTGGAT 
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Pc210 F CAACCAACCCTTTTACGGTCTC 
Pc210 R AATTAGTACGGGCGTGTGGTCT 
ADH F GTTTCCTCGTCATTGTTCTCG 
GPD F CGGTAGGTATTGATTGTAATTCTG 
CYC R GTTGTCTAACTCCTTCCTTTTCG 
T213A F GGCTAGATGCTTGTGCAGACCCGGACAAGG 
T213A R CCTTGTCCGGGTCTGCACAAGCATCTAGCC 
 
2.1.4 Reagents used in this study 
 All chemicals and reagents were ordered from Sigma-Aldrich ltd, unless otherwise 
stated. 
2.1.4.1 Hydrogen Peroxide 
A 30% (w/w) stock of H2O2, 9.8 M was ordered and kept at 4 °C This was diluted in 
in molten agar (50 - 60 °C) to the desired molarity. 
2.1.4.2 Ampicillin  
Ampicillin salt was added to 100 ml dH2O to create a 50 mg/ml stock, which was filter 
sterilised and stored at -20 °C until required. 
2.1.4.3 100 % Trichloroacetic acid solution 
Trichloroacetic acid (20 g) was added to 9.1 ml of dH2O and let dissolve to create a 
100 % TCA solution.  
2.1.5 Microbiological reagents used in this study  
2.1.5.1 Yeast Peptone Dextrose (YPD) 
Bacto-yeast extract (10 g, BD & Co.), bacto-peptone (20g, BD & Co.) and D-glucose 
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2.1.5.2 YPD Agar  
 Bacto-Agar (20 g, BD & Co.) was added to liquid YPD prior to being made up to 1 L 
with dH2O. This was then autoclaved, allowed to cool and poured into sterile petri dishes 
under sterile conditions till it had solidified. Subsequent agar plates were stored at 4 °C until 
required. 
2.1.5.3 Dropout Mix  
 The following amino acids (2 g) were added to a sterile pestle and mortar (Table 2.4) 
where they were ground and mixed and stored at RT: 
Table 2.4 Amino acids required for dropout mix 
 Amino Acid  
Alanine, Arginine, Aspartic acid, Cysteine, Glutamic acid, Glutamine, Isoleucine, 
Phenylalanine, Proline, Serine, Threonine, Tyrosine, Valine, Inositol, para-aminobenzoic, 
lysine 
 
2.1.5.4 Amino Acid Supplemental Stocks 
 Strains used in this study are auxotrophic for particular amino acids depending on their 
genotypes background (Table 2.1). Working stocks of amino acid supplemental stocks were 
made as described (Table 2.5). 
Table 2.5 Amino acid stock concentrations and final concentration when added to SC 
media 
Amino acid Working Stock 
Conc. 
Volume added to 
1 L SC media 
Final Amino acid 
Conc. (µg/ml) 
L-Leucine 1 g/100 ml 10 ml 100 
L-Histidine 1 g/100 ml 2 ml 20 
L-Uracil 0.2 g/100 ml 10 ml 20 
L-Methionine 1 g/100 ml 2 ml 20 
  L-Lysine 0.2 g/100 ml 10 ml 20 
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2.1.5.5 Synthetic Complete (SC) media  
Yeast nitrogen base (YNB) without amino acids (6.7 g, BD & Co.), D-glucose (20 g) 
and dropout mix (1.5 g) were added to 800 ml dH2O and dissolved. This was supplemented 
as required with the necessary amino acids using stocks as described in Section 2.1.5.4. This 
was topped up to 1 L using dH2O, autoclaved and stored at room temperature. 
2.1.5.6 SC agar 
Bacto-Agar (20 g) was added to liquid SC prior to being topped up to 1 L using dH2O. 
This was autoclaved and then allowed to cool. SC agar plates were stored at 4 °C. 
2.1.5.7 Phosphate Buffered Saline (PBS) 
 PBS (1 X tablet; Oxoid Ltd., Basingstoke, Hampshire, England) was added to 200 ml 
of dH2O and autoclaved. PBS was stored at room temperature until required. 
2.1.5.8 Phosphate Buffered Saline-Tween-20 (PBST) 
 Tween-20 (0.1 ml) was added to 200 ml PBS (Section 2.1.3.7). This was filter 
sterilised through a 45 µm filter to create 50 ml aliquots which were stored at room 
temperature. 
2.1.5.9 Luria-Bertani (LB) Broth  
 LB broth (25 g, Difco, Maryland, USA) was added to 1 L dH2O and dissolved with 
the aid of a magnetic stirring rod. LB solution was autoclaved and stored at 4 °C. 
2.1.5.10 LB Agar 
 LB agar (40 g Difco, Maryland, USA) was added to 1 L dH2O and dissolved with the 
aid of a magnetic stirring rod. LB agar was autoclaved and once cool, was poured (25 ml) 
under sterile conditions into petri dishes. Solidified agar plates were stored at 4 °C until 
required. 
2.1.5.11 LB Broth + Ampicillin 
 LB broth was made up as previously described in Section 2.1.5.9. Before inoculation, 
using a 50 mg/ml ampicillin stock, ampicillin (0.1 mg/ml) was added and LB-agar-ampicillin 
was poured (25 ml) under sterile conditions into petri dishes. 
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2.1.5.12 LB Agar + Ampicillin 
LB agar was made up as previously described in Section 2.1.5.10. Before inoculation, 
using a 50 mg/ml ampicillin stock, ampicillin (0.1 mg/ml) was added to 5 ml LB broth. 
2.1.5.13 Sabouraud-Dextrose (SB) media 
 Sabouraud-Dextrose media (30.12 g ; Oxoid Ltd, Basingstoke, Hampshire, England) 
was added to 800 ml dH2O and dissolved. Solution was made up to 1 L and autoclaved. SB 
media was stored at 4 °C until required. 
2.1.6 Agarose Gel Electrophoresis Reagents  
2.1.6.1 50 X Tris-Acetate (TAE) 
 Trizma base (342 g) was added to 57.1 ml of glacial acetic acid and 100 ml of EDTA 
(0.5 M). This was pH adjusted to pH 8.0 and made up to 1 L with dH2O and stored at room 
temperature. 
2.1.6.2 1 X TAE 
 50 X TAE (20 ml) (Section 2.1.4.1) was added to 980 ml dH2O. 1 X TAE was mixed 
and subsequently stored at room temperature until required.  
2.1.6.3 0.8 % (w/v) Agarose Gel 
Agarose (0.4 g) was dissolved in 50 ml 1 X TAE (Section 2.1.4.1). This was brought 
to boil until all the agarose had been dissolved then allowed to cool until ‘hand hot’. Ethidium 
bromide was added by taking 4 µl of a 10 mg/ml stock which was mixed into the molten agar 
by pouring the molten agar into a gel casting tray allowing for visualisation of DNA under 
U.V. lamp. 
2.1.7 Yeast Transformation Buffers 
2.1.7.1 50 % (w/v) Polyethylene Glycerol (PEG) 
PEG (50 g) was dissolved in 100 ml dH2O, autoclaved and stored at room temperature. 
2.1.7.2 1 M Lithium Acetate 
Lithium acetate (6.59 g) was dissolved in 100 ml of dH2O, autoclaved and stored at 
room temperature. 
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2.1.7.3 100 mM Lithium Acetate 
 1 M Lithium acetate (1 ml) (Section 2.1.5.2) was added to 100 ml of dH2O that was 
sterile filtered with a 45 µm filter. 
2.1.8 E. coli Transformation Buffer  
2.1.8.1 Transformation Storage Buffer (TSB) 
PEG (1 g), Dimethyl sulfoxide (50 µl), Glycerol (2 ml), 20.4 mg of Magnesium 
chloride (MgCl26 H2O) and 24.6 mg of Magnesium sulphate (MgSO47 H2O) was made up to 
10 ml using LB broth. 
2.1.8.2 5 X KCM  
0.5 M Potassium chloride (KCl), 0.15 M Calcium chloride (CaCl22H2O) and 0.25 M 
Magnesium chloride (MgCl26 H2O). 
2.1.9 Sodium Dodecyl Sulphate-Poly Acrylamide Gel Electrophoresis (SDS-PAGE) 
Reagents  
2.1.9.1 12.5 % SDS-PAGE gel 
The materials for both running gel and stacking gel as in table 2.6 and table 2.7 were 
prepared as follows: 4 X running buffer was prepared by adding 34.75 g of Tris base and 4g 
SDS was dissolved in 500 ml of dH2O, pH adjusted to 8. 10 % Ammonium persulfate (APS) 
40 mg was added to 400 ul of dH2O and vortexed into solution. 2 X Stacking buffer was 
prepared by adding 15 g of Tris base and 0.2 g SDS was dissolved in 500 ml of dH2O, pH 
adjusted to 8. 
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Table 2.6 Running gel 
Reagents Volume 
4X Running Buffer 2.5 ml 
dH2O 
3.3 ml 
Protogel 4.15 ml 
10 % ammonium persulphate 100 µl 
TEMED 10 µl 
 
Table 2.7 Stacking gel 
Reagents Volume 
2X Stacking Buffer 1.25 ml 
dH2O 
0.825 ml 
Protogel 400 µl 
10 % ammonium persulphate 25 µl 
TEMED 2.5 µl 
 
2.1.9.2 1 X Running Buffer 
Diluted 4 X running buffer (250 ml) by adding 750 ml of dH2O. 
2.1.9.3 6 X Protein Sample Buffer 
Made up to 50 ml in milliQ H2O. 
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Table 2.8 Preparation of 6X protein sample buffer 
Reagents Quantity 
2X Stacking Buffer 21 ml 
SDS 2.7 g 
DTT 385 mg 
Bromophenol Blue 3.6 mg 
  Glycerol 21 ml 
2.1.9.4 Coomassie Brilliant blue stain solution 
Methanol 30 % (v/v), Acetic Acid 10 % (v/v), and Coomassie brilliant blue G-250 0.1 
% (w/v) was made up to a volume of 500 ml with dH2O. 
2.1.9.5 Detaining solution 
Ethanol (100 ml) and acetic acid (100 ml) was added to 800 ml of dH2O. 
2.1.10 Western Blot Reagents  
2.1.10.1 Towbin Electrotransfer Buffer 
Tris (3.03 g), glycine (14.4 g) and methanol (200 ml) was adjusted to 1 L with dH2O. 
2.1.10.2 Blocking buffer 
Marvel 5 % (w/v) solution was made by adding marvel (1 g) and Bovine serum 
albumin 1 % (w/v) was made by adding BSA (200 mg) to 20 ml of PBST (Section 2.1.3.8). 
2.1.10.3 Antibody Buffer 
 Marvel 1 % (w/v) was made by adding marvel (100 mg) and Bovine serum albumin 1 
% (w/v) was made by adding BSA (100 mg) to 10 ml of PBST (Section 2.1.3.8). 
2.1.10.4 Primary Antibody  
 Anti-His from mouse (Biolegend Cat no: 652502) was used at a dilution of 1/3000 in 
antibody buffer (Section 2.1.8.3). 
2.1.10.5 Secondary Antibody  
 Horse radish peroxidase (HRP) anti-mouse IgG from Goat (Biolegend Cat no: 
405306) was used at a dilution of 1/3000 in antibody buffer (Section 2.1.8.3). 
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2.1.11 High Power Liquid Chromatography (HPLC)  
2.1.11.1 HPLC System 
RP-HPLC analysis was conducted using a Shimadzu prominence HPLC system using 
a SPD-M20A diode array detector. 
2.1.11.2 Mobile Phase Buffer A 
 Trifluoroacetic (1 ml) acid (TFA) added to 1 L of mH2O. 
2.1.11.3 Mobile Phase Buffer B 
 Acetonitrile (1 L) had 1 ml of TFA added to it. See 2.1.12.1. 
2.1.11.4 Stationary phase 
An Agilent Eclipse XDA-C18 column was used for all RP-HPLC work. 
2.1.12 Mass Spectrometry Reagents  
2.1.12.1 Destaining Buffer 
 Ammonium bicarbonate (0.79 g) was dissolved in 100 ml deionised H2O and diluted 
1:1 HPLC grade acetonitrile. This was made fresh on the day. 
2.1.12.2 Trypsin Reconstitution Buffer  
 Ammonium bicarbonate (10 mM and 10 % (v/v) HPLC grade acetonitrile was brought 
to a final volume of 10 ml using deionised H2O. This was made fresh on the day. 
2.1.12.3 Trypsin Digestion Buffer  
 Trypsin (20 µg) was diluted in a 1.5 ml reconstitution buffer giving 13 ng/µl working 
stock. Surplus trypsin digestion buffer was stored at -20 °C. 
2.1.12.4 50 mM Ammonium Bicarbonate  
Ammonium bicarbonate (200 mg)was dissolved in 50 ml deionised H2O, on the day. 
2.1.12.5 Extraction Buffer  
A 5 % (v/v) formic acid and HPLC grade acetonitrile were mixed 1:2 (v/v). This was 
made fresh on the day. 
2.1.12.6 0.1 % Formic Acid  
A 0.1 % (v/v) formic acid solution was prepared by adding 10 µl of formic acid to 10 
ml of deionised H2O on the day. 
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2.1.13 Zip Tip buffers   
2.1.13.1 Resuspension Buffer  
TFA (5 µl) was placed in 995 µl of milliQ H2O in a 1.5 ml microfuge tube. 
2.1.13.2 Equilibration and Wash Buffer  
TFA (1 µl) was placed in 999 µl of milliQ H2O in a 1.5 ml microfuge tube. 
2.1.13.3 Wetting Buffer  
Acetonitrile (800 µl) was placed in 199 µl of milliQ H2O with 1 µl of TFA in a 1.5 ml 
microfuge tube. 
2.1.13.4 Elution Buffer  
Acetonitrile (600 µl) was placed in 399 µl of milliQ H2O with 1 µl of TFA in a 1.5 ml 
microfuge tube. 
2.1.13.5 Buffer A 
Acetic acid (5 µl) was placed in 975 µl of milliQ H2O with 20 µl of acetonitrile in a 
1.5 ml microfuge tube. 
2.2 Methods  
2.2.1 Microbiological Methods  
2.2.1.1 S. cerevisiae growth, maintenance and storage  
 S. cerevisiae strains were grown on YPD agar plates (Section 2.1.3.2) at 30 °C in a 
static incubator for 48 h in the dark. For liquid cultures, S. cerevisiae strains were inoculated 
in liquid YPD (Section 2.1.3.1) at 200 rpm (Innova 4000 orbital shaker, New Brunswick 
Scientific, UK) at 30 °C. Growth and maintenance of those strains which contained plasmids 
was carried out using SC media (Section 2.1.3.5) or SC agar (Section 2.13.6) lacking an 
appropriate amino acid to maintain selection for that particular plasmid. Working stocks of 
strains were kept at 4 °C for short term use and were re-inoculated every few weeks. Long 
term stocks were generated using 500 µl of freshly grown cells, mixed with 40 % (v/v) 
glycerol in a 1.5 ml tube. This was then flash frozen using liquid N2 and stored at -70 °C until 
required.  
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2.2.1.2 E.coli growth maintenance and storage  
E. coli cells were grown on LB-ampicillin plates (Section 2.1.3) and grown at 37 °C, 
or in LB-amp broth (Section 2.1.3.23) at 37 °C shaking. Working stocks were kept at 4 °C for 
short term use. Long term stocks were generated using 500 µl of freshly grown cells and 
mixed with 40 % glycerol (Section 2.1.3.) This was then ‘flash frozen’ in liquid Nitrogen and 
stored at -70 °C before use.  
2.2.1.3 Measuring S. cerevisiae cell density  
Overnight cultures were diluted 1/50 by adding 100 µl of culture to 4.9 ml fresh media. 
The OD600 nm = was then measured using a spectrophotometer (Eppendorf). Depending on the 
OD600 nm required, more culture would be added to increase the OD or removed and more 
media added in its place to lower the OD until at a desired concentration. This was carried out 
under sterile conditions. 
2.2.1.4 Dot Assay/Comparative growth analysis 
Overnight cultures (5 ml) were diluted the next morning to an OD600 nm = 0.2 in 5 ml 
of fresh media. Diluted cultures were incubated at 30 °C at 200 rpm until at a concentration 
of 3 x 106 cells/ml. Cultures were pelleted by centrifugation at 1677 g for 5 min and re-
suspended to a concentration of 5 x 106 cells/ml.  Using a 96 well plate (Starstedt), 200 µl 
neat culture was added to wells in column ‘1’. In the wells of column 2-6 inclusive, 160 µl of 
fresh media was added. Using a multi-channel pipette, a 1/5 serial dilution was carried out by 
removing and adding 40 µl from well A1 through to well A6. With a sterilised 96 well 
replicator (Sigma), cells where transferred under sterile conditions. Cells were allowed to dry 
before being incubated at 30 °C static for 48 h. 
2.2.2 Molecular Biological Methods  
2.2.2.1 Polymerase Chain Reaction 
PCR was employed to amplify fragments of DNA for cloning into plasmids and 
confirmation of cloning. For amplification of DNA fragment for cloning into plasmids a high 
proof read Taq polymerase was used NEB Q5 Taq polymerase. All other PCR reactions used 
Bioline My Taq polymerase. 
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PCR using NEB Q5 Taq polymerase 
5X Q5 Reaction Buffer    5 µl 
10 mM dNTP’s     0.5 µl 
10 µM Forward Primer    1.25 µl 
10 µM Reverse Primer    1.25 µl 
Template DNA     50 – 500 ng 
Q5 High Fidelity DNA polymerase   0.2 µl 
Nuclease free water     to total volume of 25 µl 
PCR using Bioline My Taq polymerase 
5X My Taq Reaction Buffer (with dNTP’s) 5 µl 
20 µM Forward Primer    0.5 µl 
20 µM Reverse Primer    0.5 µl 
Template DNA     50 – 500 ng 
My Taq DNA polymerase    0.2 µl 
Nuclease free water     to total volume of 25 µl 
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PCR reaction cycle 
A typical PCR reaction cycle using NEB Q5 Taq polymerase used unless otherwise 
stated: Step1: 95 °C (denaturing) 5 min; Step 2 95 °C (denaturing) 1 min; Step 3: 55 °C* 
(annealing) 1 min 30 sec; Step 4 72 °C ** (extension) 30 sec per kb of amplified DNA; repeat 
X30 cycles from step2; Step 5: 72 °C (extending) 10 min. 
* Annealing temperatures were calculated by setting 4 °C below the lowest melting 
temperature (Tm) of the primers being used. 
** Extension for My Taq DNA polymerase was chosen as 1 min/kb of target DNA. 
The extension time was also reduced to 68 as per suppliers °C as per supplier’s 
recommendations. 
2.2.2.2 Site-directed mutagenesis of plasmid DNA 
Site directed mutagenesis (SDM) is an effective molecular biology technique that can 
be used to incorporate nucleotide changes in a fragment of the DNA molecule thus generating 
mutants of interest at specific amino acid residues. The technique was first described by 
Hutchison et al., (1978). Complementary primer pairs were designed to anneal to egtA 
causing a mismatch of base pairs. The primer pairs were designed to replace Thr213 with 
alanine which is unable to undergo phosphorylation. Plasmid DNA was prepared as described 
in Section 2.2.4.1 and PCR reactions were carried out using a PTC-200 Peltier Thermal Cycler 
(MJ Research) as described below using primers the primers T213A F and T213A R (Table 
2.3). The PCR products were treated with 1 µl of Dpn1 (New England Biolabs) and 2.5 µl of 
NEB buffer 4 (New England Biolabs) and incubated for 2 h at 37 °C to get rid of any 
methylated parental DNA. Approximately 8 µl of PCR product was transformed into the super 
competent E. coli strain xl1-Blue using the long transformation method as described in Section 
2.2.4.5. Four colonies were picked randomly from each transformation and the plasmid DNA 
extracted as described in Section 2.2.4.1. The plasmid DNA was then quantified using a 
Nanodrop Spectrophotometer (Mason Technology) and sent for sequencing to LGC genomics 
as described in Section 2.2.2.3. Using the primers GDP promoter F and CYC promoter R 
(Table 2.3). After confirmation of the presence of the required mutation by DNA sequence 
analysis, the plasmid was then transformed into yeast for phenotypic characterisation. The 
plasmids were also fully sequenced to confirm that there is no other undesired mutations.  
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PCR Mixture (25 µl)    PCR Cycle (Time in min) 
PFU Ultra Buffer (Stratagene) = 1 X  Step 1 = 95  °C 1:00 
dNTP mix (Promega) = 0.2 mM each Step 2 = 95  °C 0:30  
Forward primer = 100 ng   Step 3 = 55  °C 1:00 
Reverse primer = 100 ng   Step 4 = 68  °C 2:00 per kb 
Template DNA = 50 ng   Step 5= Go to step 2, 12 times 
HF PFU ULTRA (Stratagene) = 2.5 U Step 6 = 68  °C 7:00  
Molecular grade H2O adjusted to 25 µl Step 7 = 4 °C forever 
      Step 8 - end 
2.2.2.3 Sequencing of plasmid DNA 
Plasmid DNA was prepared as in Section 2.2.4.1. Approximately 1 µg of DNA was 
mixed with 20 pmol of an appropriate primer and the final volume was adjusted to 15 µl with 
sterile dH2O in a 1.5 ml microfuge tube. The microfuge tubes were then labelled with prepaid 
barcodes purchased from LGC Genomics and the samples were sent to Sanger sequencing 
(LGC genomics Germany). DNA was sequenced by dye-terminator sequencing and results 
were available for downloading after 3-5 days from LGC- Genomics website. Primers were 
designed to cover the complete sequence of egtA.  
2.2.3 DNA Gel Electrophoresis 
2.2.3.1 Preparation of a 0.8 % Agarose Gel 
 Gels were cast in a Biorad casting tray by adding 0.4 g electrophoresis agarose into 50 
ml. (0.8 % w/v) 1X TAE buffer (Section 2.1.5. ) and heated to boiling using a microwave set 
at maximum power for 1 min. This was allowed to cool till hand hot and was poured into the 
casting mould. 1 µl of a 10 mg/ml ethidium bromide was added and mixed into the agar 
solution by stirring gently. A well comb was then secured in place to create wells for the 
addition of samples, and allowed to set for 30 min. 
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2.2.3.2 Loading and Running of Samples 
 Before loading into a gel, DNA samples must first be mixed with 6X loading dye 
(NEB). To estimate sample size, a molecular weight marker was also added to one lane. A 1 
kb DNA ladder (NEB), was used throughout this study. Samples were loaded and run at 90 V 
for 45 min depending on the size of the expected sample. 
2.2.3.3 DNA Gel Extraction 
 Bands were excised using a sterile scalpel and transferred to a sterile, pre weighed, 2 
ml microfuge tube. The weight of the gel slice was then weighed and treated using QIA quick 
gel extraction kit (Qiagen) with the reagents and columns provided as per manufacturers 
guidelines. DNA was eluted using 30 µl sterile dH2O added directly to the centre of the spin 
column, leaving to stand for 1 min. This was centrifuged at 16099 g for 1 min and the eluted 
DNA was stored at -20 °C until required. 
2.2.3.4 DNA Restriction Digest 
 DNA restriction digest was used for the release of target regions contained within a 
plasmid, linearizing a plasmid and to enable the subsequent ligation of genes of interest into 
plasmid vectors. Restriction enzymes and buffers (NEB) were used as per instructions e.g.: 
DNA 1-5 ug; enzyme 1. 1 µl, enzyme 2. 1 µl; 10 X buffer 1.5 µl; sterile dH2O to total volume 
of 15 ul. Reactions were usually carried out at 37 °C for 3 hours. 
2.2.3.5 DNA Ligation 
Genes to be cloned into plasmid vectors were ligated with T4 DNA ligase (Promega). 
After the creation of compatible fragments by restriction digest (Section 2.2.3.4) digested 
DNA fragments were separated via gel electrophoresis (Section 2.2.3.1.). Correctly sized 
bands were excised from the gel (Section 2.2.3.3.). DNA fragments were ligated using T4 
DNA ligase (Promega) as per manufacturer’s guidelines. After double digestion both ends of 
double stranded DNA will have a single stranded overhang if they are cohesive ends. All 
digested DNA samples used in this study possessed cohesive ends. Ligation reactions were 
carried out using the formula 
(ng of vector)(kb size of insert) X 3 = ng of insert 
 (kb size of vector) 
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2.2.4 Generation of Competent Cells  
2.2.4.1 Competent S. cerevisiae cells  
 S. cerevisiae cells were inoculated in 5 ml YPD (Section 2.1.3.1) at 30 °C shaking. 
The next morning cultures were added to 50 ml of fresh media in a 250 ml conical flask at an 
OD600 nm of 0.4. Incubated cells for approximately 3 h until a concentration of 1 x 10
7 cells/ml 
was reached. The culture was then split into two 25 ml fractions in two 50 ml falcon tubes. 
Cells were centrifuged at 1677 g for another 5 min and subsequently washed with 25 ml dH2O 
then centrifuged again at 1677 g for another 5 min. Supernatants were removed from each 
respective tube, and the cell pellets were resuspended in 1 ml 100 mM lithium acetate (Section 
2.1.6). Resuspended cells were transferred to microfuge tubes and centrifuged at 18894 g for 
5 sec. Resulting pellets were resuspended in 500 µl 100 mM lithium acetate and stored at 4 
°C for no longer than 5 days.  
2.2.4.2 S. cerevisiae transformation of competent yeast 
Competent yeast (50 µl) from Section 2.2.4.1 were centrifuged for 5 sec at 18894 g 
and any residual lithium acetate was aliquoted out. The following was added to the cell pellet 
in order: 240 µl 50 % (w/v) PEG (Section 2.1.6.); 36 µl 1 M lithium acetate (Section 2.1.6. ); 
25 µl single stranded carrier DNA (2 mg/ml stock) and 50 µl DNA/dH2O. After all 
components were added yeast were vortexed into solution and incubated at 30 °C for 30 min. 
This was then treated to a 42 °C heat-shock (Accublock Digital Dry bath, Labnet International 
Inc) for 30 min. Mixtures were subsequently centrifuged at 18894 g for 15 sec and 
supernatants were removed. Resulting pellets were re-suspended in 200 µl dH2O, plated onto 
selective agar plates incubated for 48 h at 30 °C static. 
2.2.4.3 Competent E.coli cells 
 E. coli (Top ten) cells were inoculated in 5 ml LB broth (Section 2.1.3) and incubated 
at 37 °C, shaking overnight. Inoculated 500 µl to fresh 25 ml of LB media and incubated again 
at 37 °C at 200 rpm. This was left until an OD600 nm of 0.6 is reached. Cells were centrifuged 
at 1677 g for 10 min at 4 °C. Supernatant was discarded and while on ice cell pellet was 
resuspended in 5 ml of TSB for 10 min (Section 2.1.8.1). Transferred to pre chilled micro 
centrifuge tubes, snap froze and stored at -70 °C. 
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2.2.4.4 Quick E. coli Transformation 
LB-Amp-agar was pre heated to 37 °C for 1 hr prior to transformation. 1-5 µl of 
plasmid DNA was added to 50 µl of pre thawed E.coli. Incubated on ice for 10 min then plated 
onto pre-heated LB-amp-agar plates and incubated overnight at 37°C. 
2.2.4.5 Long E. coli Transformation 
DNA 1-3 µl (100 ng-1 µg) typically from a ligation reaction is added to 50 µl of 
competent E. coli and 10 µl of 5 X KCM (Section 2.1.8.2). Vortex mixture briefly and leave 
on ice for 20 min. Keep at room temperature for 10 min then, add 500 µl of LB media and 
incubate at 37 °C for 45- 60 min. Centrifuge 8050 g for 1 min and most of the supernatant 
leaving approximately 100-200 µl. Resuspended cells on LB-amp-agar plate and incubate 
overnight at 37°C. 
2.2.5 Plasmid Isolation in E. coli  
2.2.5.1 Plasmid Isolation and Purification from E. coli 
A single colony from a transformed E. coli Amp-agar plate (Section 2.1.5.12) was 
inoculated overnight in 5 ml of LB broth + Ampicillin (Section 2.1.5.11) and incubated at 37 
°C overnight. Cells were pelleted via centrifugation for 5 min at 1677 g. To elute the plasmid 
DNA 30 µl of dH2O was added directly to the centre of the spin column and let stand for 1 
min at room temperature. Plasmid DNA was collected by centrifugation at 18894 g for 1 min 
and stored at -20 °C until required. 
2.2.6 RNA Analysis  
All other materials used were double autoclaved  and treated with RNase Zap™ 
(Invitrogen) prior to use to remove any unwanted RNases. All workplaces were thoroughly 
washed with 70 % (v/v) ethanol and RNase Zap for the same reason. 
2.2.6.1 RNA extraction from A. fumigatus 
RNA was extracted from A. fumigatus using the Qiagen RNeasy plant mini kit as per 
manufacturer’s instructions. All buffers and filter columns were supplied with the kit as well 
as the constituents of the buffers used. SB media (50 ml) as in Section 2.1.5.13) was inoculated 
with 500 µl of conidial suspension and incubated overnight at 37 °C shaking. Mycelia were 
harvested through sterile Mira-cloth and excess medium was washed off using dH2O. Mycelia 
were then dried using sterile tissue paper, wrapped in tin foil and snap froze in liquid nitrogen. 
Samples could be stored from this point at 70°C until required. Frozen mycelia were placed 
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in respective pestle and grinded till at a powdery consistency. Powdered tissue (100 mg) was 
added to a sterile 2 ml microfuge tube and kept in an ice bucket containing liquid N2 until 
ready to proceed. Added 450 µl of buffer RLC (containing ß-mercaptoethanol added prior to 
first use) and vortex tube vigorously until homogenous.  
RNA was eluted by adding 30 µl of RNase free water directly through the centre of 
the column and let it stand for 1 min. The column was then centrifuged at 11180 g for 1 min 
and the resulting eluent was aliquoted back up using a sterile tip and passed through the 
column again to increase RNA yield. RNA was then stored at -70 °C until required. 
2.2.6.2 RNA extraction from S. cerevisiae 
Yeast strains were inoculated overnight in 5 ml in SC media. The following day RNA 
was extracted using Qiagen RNAeasy kit. The overnight culture was harvested at 2500 rpm 
for 5 min at 4 °C. Pellets were then resuspended in 600 µl of buffer RLT and transferred to a 
1.5 ml microfuge tube and left on ice. An equal volume of 0.5 mm soda lime glass beads were 
added to the 1.5 ml microfuge tubes and vortexed tubes for 30 s and left on ice for 30 s. This 
was repeated 5 times to ensure that the pellets were completely disrupted. The samples were 
then centrifuged at 4 °C for 3 min at 11180 g and the supernatants transferred to 1.5 ml 
microfuge tubes. One volume of 70 % molecular grade ethanol was added to the lysate, mixed 
and transferred to spin columns and centrifuged at 4 °C for 15 s at 11180 g. This was followed 
by addition of 700 µl of buffer RWI and samples were centrifuged again at 4 °C for 15 s at 
11180 g. Then 500 µl of buffer RPE was added to the spin columns and centrifuged at 4 °C 
for 2 min at 11180 g. The RNA was then eluted in 40 µl RNase free H2O by centrifugation at 
11180 g for 2 min at 4 °C.  
2.2.6.3 DNAse Treatment of RNA Samples 
 RNA samples extracted from A. fumigatus (Section 2.2.6.1) were DNase treated using 
a DNase kit purchased from Sigma Aldrich Ltd. 500 ng A. fumigatus was brought to a final 
volume of 8 µl using DEPC treated distilled water in a RNase free sterile 500 µl microfuge 
tube. To this, 1 µl 10 X reaction buffer and 1 µl DNase were added and were incubated at 
room temperature for 15 min. Afterwards, 1 µl stop solution (part of kit) was added and 
subsequently incubated at -70 °C for 10 min. Samples were placed on ice for at least 1 min 
and stored at -70 °C until required. 
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2.2.6.4 cDNA Synthesis 
 cDNA was synthesised using the qScriptTM cDNA supermix (Quanta Biosciences). 
All reagents and buffers contained a single reagent supplied in the kit. cDNA was synthesised 
as per manufacturer’s instructions. 500 ng of RNA (Section 2.2.6.1) which had been DNase 
treated (Section 2.2.6.2) was added to DNase and RNase free 500 µl microfuge tubes. To this 
4 µl of the qScriptTM cDNA Supermix 5 X was added and topped up to a final volume of 20 
µl using diethyl-pyro carbonate (DEPC) treated dH2O. Samples were vortexed briefly and 
centrifuged for a few seconds to collect all of the reaction mix. They were then incubated 
using a PCR cycler using the following incubation protocol: 5 min at 25 °C; 30 min at 42 °C 
5 min at 85 °C; hold at 4 °C. Once completed the cDNA is now ready for use. 
2.2.7 Proteomic Analysis 
2.2.7.1 Protein extraction from S. cerevisiae  
 Yeast strains were cultured overnight in 5 ml YPD or selective media at 30 °C, shaking 
200 rpm in triplicate. The following day cells were diluted in 25 ml of fresh media to an OD 
600 nm of 0.2 as incubated before for a chosen time period. Cells were harvested by 
centrifugation at 4 °C; 5 min; 1677 g (5810R Eppendorf AG Hamburg). Pellets were 
resuspended in 1 ml of milliQ H2O and pipetted into 2 ml tubes. Then centrifuged at 4 °C; 1 
min; 18894 g (5415D Eppendorf AG Hamburg) and discarded supernatant. The wet weight 
of each culture was recorded and cells were then resuspended in 1 ml of milliQ H2O. The 
following formula was used to work out what volume to take for 50 mg of cells and placed in 
fresh tube, centrifuged as above and supernatant removed. 
 
Lysis buffer was prepared by adding 3 µl of protease cocktail inhibitor (P8215; for 
use with fungal and yeast extracts) per ml of Cell Lytic TM Yeast cell lysis reagent. DTT (10 
mM) is also added to improve final protein yield, however DTT is not added if lysates are to 
be used in the ergothioneine alkylation assay as it interfered with 5’-Iodacetamidofluorescein 
labelling of ergothioneine. The prepared lysis buffer (900 µl) was then added to each tube 
containing 50 mg of cells. 0.5 mm soda lime glass beads (Biospec Cat No. 11079105) were 
then added to each tube until only a small amount of room remained. Tubes were bead beaten 
using a bead beater (Retsch mm 400) for 10 sec and then chilled on ice for 1 min, and was 
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repeated 10 times. Tubes were then centrifuged at 4 °C for 10 min at 18894 g and supernatants 
were transferred to pre chilled microfuge tubes and centrifuged again as above. 
2.2.7.2 Bradford Protein Assay  
 Protein samples (Section 2.2.7.1) were quantified using the Bradford protein assay. 
Using a BSA stock (1 mg/ml) protein solutions of a known protein concentration were created 
to generate a protein standard curve in triplicate. Samples in triplicate were diluted 1:10, 2 µl 
of which was added to a 96 well plate (Starstedt). Biorad 1X protein assay (200 µl) was added 
to each sample/standard and following a 10 min incubation at room temperature, absorbance’s 
were read using a spectrometer set at A595 nm (Eppendorf Biophotometer). Protein 
concentration of samples was calculated using a plotted A595 nm versus BSA concentration 
standard curve. All protein samples were analysed in triplicate. 
2.2.7.3 Sodium Dodecyl Sulphate-Poly Acrylamide Gel Electrophoresis (SDS-PAGE) 
 12.5 % SDS-PAGE gels were prepared using one 1 mm Bio-Rad glass backplate and 
one front plate along with a 15 well combs having 44 µl sample capacity. The glass plates 
were cleaned thoroughly with 70 % ethanol and then rinsed with milliQ H2O. The glass plates 
were then sealed in a Bio-Rad Gel Cassette and a casting frame which was then filled with 
milliQ H2O to ensure the plates were sealed. The running gel was prepared first adding the 
materials in table 2.6 in order in a 50 ml falcon. Emptied plates of milliQ H2O and gently 
pipetted the mixture in falcon tube between the glass plates to a capacity of approximately 70 
% to allow room for stacking gel. MilliQ H2O was then sprayed on top of the gel to the full 
capacity of the glass plates to ensure a smooth surface on the running gel once solidified. 
Once the gel had set millIQ H2O was removed and the stacking gel was prepared as in Table 
2.7 by adding the materials in the order listed in a 15 ml falcon. The stacking gel was then 
pipetted in between the plates to maximum capacity. A 15 well comb was cleaned with 70 % 
ethanol, rinsed with milliQ H2O and placed between the plates. This was then left to set at 
room temperature for 20-30 min. 
2.2.7.4 Sample preparation and SDS-PAGE  
 Using 6X protein sample buffer (Section 2.1.7.3) samples were prepared by adding 30 
µl of cell lysate to 6 µl of protein sample buffer and boiled at 100 °C for 5 min in a digital dry 
bath. The prepared gels (Section 2.2.7.2) were removed from their casting tray and placed in 
the electrode assembly unit (Bio rad) with the thin front plates facing inwards. The electrode 
assembly was then placed in the electrophoresis tank (Bio rad). This was then filled with 1X 
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running buffer (Section 2.1.7.2) to the appropriate mark as denoted on tank. Protein samples 
were then loaded along with the protein ladder (Page ruler plus prestained protein ladder 10-
250 kDa, Fermentas, Life Sciences). The gels were then resolved in 1X protein running buffer 
at 100 V per gel for 1.5 h with a Bio-Rad Powerpac Basics. 
2.2.7.5 Western Blot 
Proteins separated in the gels were then electrophoretically transferred to 
polyvinylidene difluoride (PVDF) membranes (Perkin Elmer) and processed for blotting as 
per recommendations for use with Bio-Rad gel transfer system. To prepare for the wet transfer 
Whatman filter paper was cut into six 8 cm X 5.5 cm pieces as well as one piece of PVDF 
membrane. PVDF was then soaked in 100 % methanol for 30 s. All six pieces of filter paper 
and PVDF membrane along with two fibre pads were then equilibrated in 1X transfer buffer 
(Section 2.1.8.1) for 15 min. After a good separation of proteins was achieved the stacking 
gel was removed and the gel was rinsed in milliQ H2O. A gel membrane sandwich was 
assembled as follows cassette black side- fibre pad- 3 filter paper-gel- membrane- 3 filter 
paper- fibre pad- cassette white side. The gel- membrane sandwich was then rolled using a 
sterile pipette to remove any air bubbles. The cassette was then closed and placed in the 
transfer tank with the black side of the cassette going to the black side of the tank. The tank 
was filled with pre-chilled 1X transfer buffer and placed in an ice bucket. The cables were 
then connected to the power supply and an electric current was applied (100 V/ 350 A) for 1 
h. 
2.2.7.6 Immunoblotting 
 After the transfer of proteins to the PVDF membrane the membrane was blocked for 
1 h at room temperature rocking by placing 20 ml of blocking solution on the membrane 
(Section 2.1.10.2). After blocking the membrane was incubated overnight at 4 °C with 
primary antibody and buffer (Section 2.1.10.3). The following day the membrane was washed 
3 times in 25 ml of PBST (Section 2.1.3.8), 5 min per wash to remove excess antibody that 
might cause unspecific binding. This was followed by incubation with horse radish peroxidase 
labelled secondary antibody (Section 2.1.10.4) for 1 h. The membrane was then washed again 
3 times with PBST as described earlier. 
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2.2.7.7 Chemiluminescence  
 Chemiluminescence used the substrate ECL (Bio-Rad Clarity™ Western ECL Blotting 
Substrate kit) and was exposed using the G: BOX F3 (SYNGENE) as per manufacturer’s 
instructions. In brief the non-reflective panel was cleaned with 70 % ethanol and a fresh 
acetate sheet was then put down placing the PVDF membrane on top. The GENE SYS 
application is selected from the desktop, ECL is selected as the substrate along with ‘visible 
marker’ to co-visualise both the protein ladder and chemiluminescence. The cameras focus 
and zoom is then adjusted along with the preparation of the ECL substrate by adding 800 µl 
of peroxide solution to 800 µl of enhancer solution in 2 ml microfuge tube. The enhanced 
substrate is then evenly pipetted onto the membrane and the optimal exposure time is 
calculated by the G: BOX F3. Once exposure is complete the image is taken and exposure of 
the image can be adapted to best suit the sensitivity of antibody/substrate.  
2.2.7.8 Coomassie staining of protein gels  
 SDS-PAGE gel was rinsed with dH2O and transferred to coomassie brilliant blue stain, 
covering the gel (Section 2.1.9.4). Heated gel in microwave for 20 s (be careful not to melt 
gel) then transferred onto rocker at room temperature for 15 min. Removed coomassie and 
placed a clean piece of tissue paper in with gel (ensure gel is folded or stuck under tissue or 
will no stain or destain correctly) and added destain solution until covering gel (Section 
2.1.9.5). Place in microwave for 20 s and leave for 1 h or overnight for cleaner background. 
2.2.8 Mass Spectrometry (LC-MS) 
2.2.8.1 Protein Spot Preparation-Shevchenko method (Shevchenko et al 2006) 
SDS-Page bands were chosen based on the known size of the protein of interest EgtA 
from A. fumigatus (96.29 kDa). All reagents used were HPLC grade and 1.5 ml microfuge 
tubes were treated with acetonitrile before use. Each gel was washed once using sterile water 
before the chosen spots were cut out using a sterile scalpel and placed in a pre-washed 1.5 ml 
tube. Gel pieces were incubated in 100 µl de-staining buffer (Section 2.1.13.1), vortexed 
occasionally at room temperature for 30 min, or until all stain was removed. Acetonitrile (500 
µl) was then added to each tube and left for 10 min at room temp causing the gel pieces to 
shrink and turn white indicating removal of the majority of the coomassie stain.  
 Samples were then trypsin digested with 50 µl (or enough to cover the gel piece) 
trypsin buffer (Section 2.1.13.3) and incubated on ice for 30 min. More trypsin buffer was 
added if necessary. Gel pieces were incubated on ice for 30 min. More trypsin buffer was 
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added if necessary. Gel pieces were incubated for a further 90 min to saturate gel pieces with 
trypsin. A 50 mM ammonium bicarbonate solution (20 µl ) as in Section 2.1.13.4 was then 
added to prevent the gel piece becoming dehydrated during digestion. Gel pieces were then 
incubated at 37 °C static overnight to allow for complete trypsin digestion of sample peptides. 
 Digested peptide products were transferred to a new sterile 1.5 ml microfuge tube. 100 
µl of extraction buffer (Section 2.1.13.5) was then added to each digested gel piece and 
incubated for 15 min at 37 °C shaking to help collect any residual peptide fragments. The 
supernatant from this was added to the trypsin digest and dried overnight in a vacuum 
centrifuge. Dried extracts could be stored at – 20 °C for several months if required.    
2.2.8.2 Zip Tip of samples (for Q-Exactive MS analysis) 
Resuspended sample with 20 µl of resuspension buffer (Section 2.1.14.1). Wet zip tip 
by aspirating and dispensing 10 µl of wetting solution into the tip. This was repeated 5 times. 
Equilibrated zip tip by aspirating and dispensing 10 µl of equilibration solution onto the tip 5 
times. Bound sample to zip tip by aspirating and dispensing 10 µl of resuspended same 15 
times. Washed sample by aspirating and dispensing 10 µl of washing solution from tip to 
waste. This was repeated 5 times. Eluted sample by aspirating and dispensing 10 µl of sample 
from the tip to a fresh 1.5 ml Eppendorf. Sample was then dried down in vacuum centrifuge 
and resuspended in 20 µl of buffer A (Section 2.1.14.5). 
2.2.9 Detection and Quantification of Ergothioneine by RP-HPLC 
2.2.9.1 Alkylation of Intracellular Ergothioneine 
Cell lysates (30 µl) in Section 2.2.7.1 (made without the addition of DTT which is 
alkylated by the 5’-Iodoacetamidofluorecein (5’-IAF) label) was added to 90 µl of PBS and 
then vortexed. Samples were then centrifuged (18894 g, 5 min, at 4 °C). Each sample (50 µl) 
was placed in a fresh tinfoil covered tube and 10 µl of 3 mg/ml 5’-IAF was added (58.23 
nmol) to alkylate each sample. Samples were left in the dark for 45 min then centrifuged 
(18894 g, 5 min, at 4 °C).  
 
2.2.9.2  Alkylation of Extracellular Ergothioneine 
Sample supernatant (500 µl) was dried down in a speedy vac. Dried samples were 
resuspended in 100 µl of 200 mM sodium phosphate buffer pH 7.6 by vigorously pipetting 
up and down. Centrifuged at 18894 g for 5 min, at 4 °C. Each sample (50 µl) was resuspended, 
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taken and placed in a fresh tinfoil covered tube and 10 µl of 5’-IAF 3 mg/ml was added (58.23 
nmol) to alkylate each sample. Samples were left in the dark for 45 min then centrifuged 
(18894 g, 5 min, at 4 °C). A positive EGT control was prepared by adding 10 µl of 3 mg/ml 
5’-IAF to 50 µl of 50 µg/ml ergothioneine in 200 mM sodium phosphate buffer pH 7.6. The 
following negative controls were prepared. A 5’-IAF solution (10 µl) of 3 mg/ml was added 
to 50 µl of 200 mM sodium phosphate buffer pH 7.6. Negative control SN was also prepared 
identically and alkylated.  
 
2.2.9.3  Preparation Ergothioneine standard curve for Extracellular samples 
  EGT (20 µl) of 5 mg/ml (436.11 nmol) was added to 980 µl of negative control SN 
(SN from the yeast strain BY4741 transformed with the empty vector pRS426-GPD) giving a 
concentration of 100 µg/ml of EGT. This was prepared in duplicate. SN containing 100 µg/ml 
of EGT was serially diluted by taking 500 µl and adding 500 µl of negative control SN giving 
a concentration of 50 µg/ml of EGT. This was repeated a further 5 times giving the EGT 
concentrations 100, 50, 25, 12.5, 6.25, 3.125 and 1.56 µg/ml (Figure 2.1). All seven tubes 
were then dried down in a speedy vac 
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Figure 2.1 Serial dilution for EGT standard curve.  
 
 
Once dry, samples were resuspended by vigorously pipetting up and down in 100 µl 
of 200 mM sodium phosphate buffer pH 7.6. Samples were then centrifuged at 18894 g for 5 
min, at 4 °C. Each resuspended sample 50 µl of was taken and placed in a fresh tinfoil covered 
tube and 10 µl of 5’-IAF 3 mg/ml was added (58.23 nmol) to alkylate each sample. Samples 
were left in the dark for 45 min then centrifuged (18894 g, 5 min, at 4 °C).  
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2.2.9.4  HPLC analysis of alkylated ergothioneine 
Alkylated sample (50 µl) was placed in a HPLC vial and 30 µl was injected onto the 
column. The peak area was measured at the wavelength 442 nm. A 1 ml/min flow rate was 
used with each run which lasted a total of 40 min. Solvent B had a starting concentration of 5 
% for the first 5 min minutes which was gradually risen to 100 % at 25 min. Solvent B was 
maintained at 100 % for 3 min to wash the column. At 29 min the concentration of solvent 
was dropped to 5 % to re-equilibration the column and 5 % was maintained until the end of 
the run at 40 min. 
2.2.9.5  Calculation of extracellular EGT using the standard curve  
The average peak area of each triplicate set of samples for each time point was 
obtained and input as the ‘y’ value into the equation of the line produced by the standard curve 
x=y/554456. The product from this was divided by a 104.2 as this is the amount in µl of 
supernatant loaded onto the column the product from this was then multiplied by 1000000 
representing the culture size (µl). The final answer is then in terms mg/L. 
2.2.9.6  Calculation of intracellular EGT using the standard curve  
The average peak area of EGT at 13.8 min in 24 h BY4741426 GPD-EgtA was taken away 
from the average peak area of the control culture peak 13.8 min peak. The product was 
multiplied by 4 representing the average wet weight cell mass of the 25 ml cultures used with 
50 mg of cells used per cell lysate. The product was then input as the ‘y’ value into the 
equation of the line produced by the standard curve x= ((y-165765)/542544). The product was 
then multiplied by 40 bringing the final answer in terms of mg/L. 
2.2.9.7  TCA precipitation of intracellular alkylated ergothioneine samples 
A solution of 100 % TCA solution (15 µl) as in Section 2.1.4.3, was added to 85 µl of 
alkylated cell lysate from Section 2.2.9.1 and left at 4 °C for 3 h. Centrifuged (18894 g, 20 
min, at 4 °C). The supernatant was then removed and placed in a fresh tube.  
2.2.9.8  LC-MS analysis of alkylated ergothioneine 
Samples from Sections 2.2.9.2 and 2.2.9.5 were diluted 1 in 100 in 0.1 % water formic 
acid (Section 2.1.13.6). 60 µl of sample was then placed in spin filter tubes and centrifuged 
(18894 g, 1 min, at RT). Samples (40 µl) were then placed in Q-Exactive LC-MS vials.  
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2.2.10 Statistical evaluation of experimental data 
Statistical analysis was carried out using the software Graphpad Prism Version 6. 
The unpaired T test method was used for all significance tests. P values below P < 0.05 were 
considered significant. 
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Chapter 3 Recombinant EgtA expression in S. 
cerevisiae enables EGT biosynthesis 
Recombinant EgtA expression in S. cerevisiae 
enables Ergothioneine biosynthesis 
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3.1 Introduction 
 
 The natural product ergothioneine (EGT) was first identified in A. fumigatus by 
Gallagher et al., (2012) in a ΔgliK mutant strain of A. fumigatus where a significantly higher 
level of  ergothioneine was present in the ΔGliK strain compared to its wild type counterpart. 
Following this study, the first fungal EGT biosynthetic gene egt-1 was identified in 
Neurospora crassa by Bello et al. (2012) by comparing homologues in N. crassa to EGT 
producing genes in Actinomycetes.  A similar strategy was used to identify EGT producing 
genes in A. fumigatus by comparing N. crassa egt-1 to homologues in A. fumigatus. From this 
the EGT producing gene AFU_2G15650 denoted egtA was identified (Figure 3.1), This gene 
has domains homologous to the SAM dependant methyl transferase domain in EgtB and the 
FGE sulfatase domain identified in EgtD in M. smegmatis (Seebeck, 2010). EGTA was 
confirmed to be involved in EGT biosynthesis by deletion of the egtA gene causing ablation 
of EGT production (Sheridan et al., personal communication). 
 
 
Figure 3.1 Conserved domains of EgtA. A SAM dependant methyltransferase domain can 
be seen along with an FGE Sulfatase domain. 
 As mentioned in Section 1 EGT shows significant potential for use as a food 
preservative and as a neutaceutical. This is through its ability to detoxify ROS such as HOCl, 
singlet O2, ONOO
- and OH. as well as form stable complexes with iron and copper (Halliwell 
& Gutteridge, 2007). EGT has also been shown to extend the shelf life of fish such as tuna 
and slow the discolouration of meat (Bao et al., 2008). Another study demonstrated how ß-
amyloid peptides which damage brain tissue by causing lipid peroxidation, were significantly 
reduced by a high EGT diet in another murine model (Yang et al., 2012).  
 Hampering the use of EGT as a preservative or nutraceutical is the cost of extracting 
EGT from sources with relatively low yields making EGT costly and unavailable for use as a 
nutraceutical.  To make EGT viable for industrial use a source must be discovered that 
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produces high quantities of EGT in a reasonable time frame from which EGT can be easily 
extracted or purified. Fungal sources looked at include the king oyster mushroom Pleurotus 
citrinopileatus recorded to contain up to 113 mg/L or 14.67 mg/g (dry weight) of EGT in 
mycelium. These are highly optimised conditions of pH and nutrients with cultures incubated 
for 22 days before harvesting (Lin et al., 2015). An Egt-1 overexpression mutant of 
Schizosaccharomyces pombe was reported to have an intracellular EGT concentration of 
266.3 mg/L produced over a 20 day period with the media changed every 6-7 days (Pluskal 
et al., 2014). 
 Bacteria could also be used as an EGT source with the Cyanobacteria species 
Oscillatoria sp CCAC M1944 identified to naturally produce high quantities of EGT of 0.8 
mg/g dry weight in an unspecified time frame (Pfeiffer et al., 2011). Mycobacteria such as M. 
smegmatis were identified to secrete EGT as an extracellular metabolite as well as contain 
some intracellularly however levels were quite low for use as an industrial application with 
the largest extracellular quantity equivalent to 44 pg/105 cells (Emani et al., 2013). The 
chemical synthesis of EGT has been improved in recent years and uses histidine as the starting 
material which could prove to be reasonably cost effective (Khonde & Jardine, 2015). 
Yeast are an ideal organism to produce EGT although they do not produce it 
themselves yeast such as S. cerevisiae can produce recombinant eukaryotic proteins such as 
granulocyte macrophage stimulating factor (Celik & Calık, 2012). It was seen how 20 % of 
all recombinant protein are produced in yeast with nearly all of these being produced by S. 
cerevisiae and is seen as the best choice for fungal enzymes (Mattanovich et al., 2012). S. 
cerevisiae can carry out post translational modifications like glycosylation as well as well as 
assisting with protein folding increasing the likelihood of producing a functional protein. 
(Gellissen et al., 1992). Unlike bacteria S. cerevisiae has a track record in the fermentation 
industry and has attained the status GRAS (generally regarded as safe) so is ideal for the 
production of a potential food additive like EGT. S. cerevisiae can rapidly grow in a 
chemically defined media offering a cost effective way of producing large amounts of 
recombinant protein coupled with the use of a high copy expression vector (Demain & 
Vaishnav, 2009).  As well as this S. cerevisiae has been shown to be probiotic in the oral 
delivery of therapeutic proteins (Omara et al., 2010). 
Eukaryotes utilize enzymatic and non-enzymatic means as part of their oxidative 
defence strategy to mediate harmful ROS that are a by-product of respiration (Nordberg & 
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Arnér, 2001; Lu, 2013). One such strategy employed to mediate oxidative stress is to produce 
the enzyme superoxide dismutase which dismutes O2
- into molecular oxygen and hydrogen 
peroxide (Steinman, 1980). The tri peptide GSH a highly abundant intracellular thiol is also 
produced by S. cerevisiae and has been shown to be critical to mediating oxidation stress with 
mutants having impaired growth as well as increased sensitivity to oxidative stress (Grant et 
al., 1996). Addition of EGT to the defence of S. cerevisiae against ROS may make the 
organism more resilient to oxidative stresses. 
This project will recombinantly express the protein EgtA in S. cerevisiae and confirm 
expression of EgtA by protein mass spectrometry (Figure 3.2 A). Production of EGT in S. 
cerevisiae will be detected using the alkylating agent 5’-IAF and confirmed using mass 
spectrometry. Alkylated EGT will then be quantified using RP-HPLC analysis (Figure 3.2 B). 
Figure 3.2 A-B Project work flow diagram showing how EgtA protein and metabolite 
EGT will be detected in S. cerevisiae. 
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3.2 Cloning of egtA into the budding yeast S. cerevisiae expression vectors 
 
 The yeast shuttle expression vector p426-GPD was chosen from a range of 
centromeric  and episomal plasmids due to its established high expression of recombinant 
proteins (Mumberg et al., 1995) (Funk et al., 2002). In yeast, episomal plasmids such as p426 
-GPD the level of heterologous mRNA in the cell is determined by the copy number of the 
expression vector which is in turn controlled by the replicon (Curran and Bugeja, 2011). p426-
GPD (Figure 3.3), contains what is considered a high copy 2µ replicon derived from a natural 
yeast plasmid allowing 50+ copies per cell to propagate (Addgene, 2014). A strong promoter 
is required to drive transcription, in p426-GPD the endogenous promoter glyceraldehyde-3-
phosphate dehydrogenase (GPD) is used which is the strongest constituent promoter available 
for S. cerevisiae and greatly increases the production of recombinant protein (Mumberg et al., 
1995; Blazeck et al., 2012). Selection is maintained in p426-GPD by a URA3 marker which 
is preferable to selection through a HIS3 marker as this may become a limiting factor in the 
production of EGT as histidine is required for EGT biosynthesis. 
 
Figure 3.3 The 6.6 kb episomal S. cerevisiae shuttle vector p426-GPD used to express 
recombinant egtA. An AmpR gene for selection after cloning into E. coli is present along 
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with a URA3 gene for selection after transformation of plasmid into S. cerevisiae and the 
restriction enzyme sites Spe1 and Xho1 used as part of the cloning strategy. 
 
 
 EgtA cDNA was synthesized by GenScript (860 Centennial Ave. Piscataway, NJ 
08854 USA) and blunt end cloned into the vector PUC57. EgtA was amplified using high 
fidelity Taq polymerase with proof reading ability to ensure sequence integrity using the 
primers EgtA F and EgtA R (Table 2.3). A cloning strategy was employed using the restriction 
sites Spe1 and Xho1 at the 5’ and 3’ end respectively. PCR products were run on an agarose 
gel and separated via gel electrophoresis to check for a single band at the correct size of 2.5 
kb (Figure 3.4). 
 
Figure 3.4 PCR amplification of egtA cDNA in the plasmid PUC57. Lane 1= 10 kb NEB 
DNA ladder, lanes 2 & 3= egtA band (size 2.5 kb) amplified with high fidelity Taq, lane 4= 
negative control. 
  
The PCR products of egtA cDNA (hereafter) ‘egtA’) amplification were cleaned using 
Qiagen PCR purification kit as per manufacturer’s instructions prior to use. The cleaned PCR 
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product was digested to create the sticky ends, required when ligating the egtA insert. The 
vector p426 GPD was also digested to open the plasmid, linearizing it in preparation for 
ligation. Both insert and vector were digested with the restriction enzymes spe1 and xho1 for 
3 h at 37 °C and separated using gel electrophoresis on an agarose gel to prevent religation of 
excised fragments during ligation (Figure 3.5 A & B).  Fragments were then excised from a 
gel using Qiagen quick gel extraction kit as per manufacturer’s instructions.  
 
 
Figure 3.5 A-B Digestion product of insert egtA (A) and vector p426 GPD (B). A: Lane 
1= 10 kb NEB DNA ladder, lane 2= digested egtA; B: Lane 1= 10 kb NEB DNA ladder, lane 
2= digested p426 GPD. 
 
After gel extraction of digested egtA and p426 GPD the DNA concentration of 
samples were measured using a Nanodrop (Mason). The egtA insert was then ligated into the 
vector p426 GPD as described in Section 2.2.3.5 and left overnight at 16 °C. Following this 
p426 GPD-egtA was transformed into E. coli cells as described in Section 2.2.4.5. E. coli with 
p426 GPD-egtA were selected by their ability to grow on LB-amp-agar plates. Plasmid DNA 
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of p426 GPD-egtA was purified from transformed E. coli as described in Section 2.2.5.1.  
Plasmid DNA of p426 GPD-egtA was then transformed into the S. cerevisiae strain BY4741 
as described in Section 2.2.4.2. Successful transformants were selected by their ability to grow 
on –URA SC media. A colony PCR was carried out on selected colonies to further confirm 
that the transformation was a success, of the 5 colonies checked by PCR 4 contained egtA 
(Figure 3.6).  
  
     
Figure 3.6 Confirmation of egtA in BY4741p426 GPD-egtA by colony PCR. Lane 1= 10 kb 
NEB DNA ladder, lanes 2-5= egtA in S. cerevisiae BY4741p426 GPD-egtA (size 2.5 kb) amplified 
with high fidelity taq, lane 6= BY4741 colony that did not contain egtA, lane 7= positive 
control p426 GPD-egtA (size 2.5 kb), lane 8= negative control. 
 
3.3 Confirmation of expression of EGTA in the budding yeast S. cerevisiae  
 
To confirm egtA could be expressed in S. cerevisiae a 6X Histidine tag (His tag) was 
generated on the N-terminus of EgtA in the vector p426 GPD. The template p426 GPD-egtA 
was amplified using high fidelity Taq and the primers EgtA N terminal His tag and EgtA R 
with the restriction sites Spe1 and Xho1 at the 5’ and 3’ end respectively. Following a 
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successful transformation of p426 GPD-egtA with an N-terminal His tag into the S. cerevisiae 
strain BY4741 successful transformants were screened colony PCR (Figure 3.7) 
 
 
 
 
 
 
Figure 3.7 Presence of egtA confirmed in BY4741p426 GPD-egtA by colony PCR. Lane 1= 10 
kb NEB DNA ladder, lane 2= negative control, lanes 3, 4 & 5=  egtA His tag in S. cerevisiae 
BY4741p426 GPD-egtA (size 2.5 kb) amplified with high fidelity taq, lane 4= BY4741 colony that 
did not contain egtA His tag, lane 7= positive control p426 GPD-egtA (size 2.5 kb).  
 
Western Blot analysis to confirm the expression of EgtA (Figure 3.8).  Cultures of BY4741 
p426 GDP-egtA His tag were grown for 24 h and protein was extracted as described in Section 2.2.7.1. 
Protein was loaded onto a polyacrylamide gel as described in Section 2.2.7.4 and transferred 
onto a PVDF membrane as described in Section 2.2.7.5.  
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Figure 3.8 Western Blot confirming the expression of EgtA in BY4741p426 GPD-egtA His tag. 
Lane 1= NEB Prestained Protein ladder 175-7 kDa, lanes 2-3= EgtA His tag protein (96 kDa) 
from S. cerevisiae BY4741p426 GPD-egtA His tag cell lysate, lanes 4-7= negative control 
BY4741p426 GPD-egtA cell lysate, lane 7= positive control recombinant GliT His Tag (36 kDa) 
(Schrettl et al., 2010). Western blot visualized using a Syngene Bioimager. 
 
 To further confirm that EgtA was expressed protein analysis by mass spectrometry 
was carried out. Cell lysates were constructed from a 24 h culture and ran on a polyacrylamide 
gel. Bands were sampled from the polyacrylamide gel where EgtA was located and trypsin 
digested as described in Section 2.2.8.1. Samples were analysed on a Q-Exactive Orbitrap 
LC-MS system (Thermo Scientific) and identified peptides were analysed using Proteome 
Discoverer software (Figure 3.9). The product of the gene AFUA_2G15650, the Egt-1 
homologue denoted as EgtA in this study was identified by having a high score and 69 unique 
peptides identified exclusively to it (Table 3.1).  
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Figure 3.9 EgtA identified from protein MS analysis of S. cerevisiae BY4741p426 GPD-egtA 
His tag cell lysate. EgtA was confirmed to be produced by BY4741p426 GPD-egtA His tag with 61 % 
coverage. Both peptides form the N-and C-terminal are present highlighted in green indicating 
that EgtA is intact upon expression. 
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Table 3.1 AF293 A. fumigatus proteins identified in BY4741426 GPD-egtA His tag using 
Proteome Discoverer 
Accession Score Coverage 
% 
Identified 
Proteins 
Unique 
Peptides 
Amino 
Acids 
Molecular 
Weight 
(kDa) 
AFUA_2G15650 756.34 61.37 1 69 844 96.2 
 
 
 
3.3 Confirmation of ergothioneine production in the yeast S. cerevisiae using LC-MS 
analysis 
 Ergothioneine was detected in S. cerevisiae strain BY4741p426 GPD-EgtA by 
alkylation of EGT with the fluorescent alkylation agent 5’-Iodoacetamidofluorescein (5’-IAF) 
first used by Gallagher et al. (2012). Gallagher et al. (2012) demonstrated alkylated EGT was 
capable of being detected by RP-HPLC analysis when loaded onto a C-18 Agilent XDB- 
Eclipse column. Alkylation of EGT  with 5’-IAF the molecules hydrophobicity allowing for 
its detection with a hydrophobic stationary phase which otherwise could not be used due to 
the hydrophilic of EGT (Gründemann 2012). This method exhibits high sensitivity for the 
detection of alkylated EGT (0.15 µM) and sensitivity can be increased in combination with 
LC-MS analysis (Sotgia et al., 2013).  
 
Alkylated samples were analysed using a Q-Exactive Orbitrap LC-MS system as 
described in Section 2.2.9.6. Alkylated EGT was identified using its known fragmentation 
pattern (Figure 3.10 A-C), identified by Gallagher et al. (2012). EGT alkylated with 5’-IAF 
has been identified as having a single charged m/z of 617 (M + H)+ and a m/z of 309 (M + 
H)2+ when double protonated. The daughter ions m/z 573 and m/z 514 have also been detected 
using tandem mass spectrometry as well as their double protonated versions m/z 287 and m/z 
257 respectively (Gallagher et al., 2012).  
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Figure 3.10 A-C Alkylated EGT with 5’-IAF and identified fragments. (A) The molecular 
ion EGT-AF (M + H)+ = m/z 617 and (M + H)2+ = m/z 309 caused by double protonation of 
the molecular ion . (B) The daughter ion (M + H)+ = m/z 573 with a neutral loss of 44 from 
the loss of COO- from the molecular ion  EGT-AF with the double protonated version (M + 
H)2+ = m/z 287. (C) EGT-AF (M + H)+ = m/z 514 with a neutral loss of 103 from with the loss 
of COO- and N(CH3)3
+ and the double protonated version (M + H)2+ = m/z 257. 
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Cultures of BY4741p426-GPD-egtA were grown for 24 h and cell lysates were prepared 
without the addition of DTT. Alkylated lysates were then examined for the presence of 
intracellular EGT by LC-MS analysis. Examination of the full scan mass spectra identified 
alkylated EGT in the double protonated form of the molecular ion m/z 309 at a retention time 
of 24 min (Figure 3.11). Tandem mass spectrometry of m/z 309 revealed the daughter ions 
m/z 257 and 287 further confirming alkylated EGT was present (Figure 3.12).  Neither m/z 
617 nor m/z 309 was detected in the negative control culture BY4741p426-GPD (Figure 3.13). 
 
Figure 3.11 Identification of the double protonated form of alkylated EGT (M + H)2+ = 
m/z 309 in BY4741p426-GPD-egtA cell lysate. Full scan (MS) of BY4741p426-GPD-egtA alkylated 
cell lysate identified at a retention time of 24 min (A) the double protonated form of alkylated 
EGT m/z 309 (B). 
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Figure 3.12 Tandem mass spectrometry of m/z 309 identifies the daughter ions m/z 287 
and m/z 257 in cell lysate of BY4741p426-GPD-egtA. MS2 of m/z 309 produced the predicted 
daughter ions m/z 287 and m/z 257 confirming the intracellular presence EGT. 
 
 
Figure 3.13 Full scan for m/z 309 and m/z 617 reveals neither is present in the control 
culture BY4741p426-GPD. Full scan mass spectra of the control culture BY4741p426-GPD did not 
contain m/z 309 identified at a retention time of 24 min or m/z 617. 
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Culture supernatant was extracted and alkylated as described in Section 2.2.9.2. 
Alkylated supernatant was then examined for extracellular EGT using the Q-Exactive 
Orbitrap LC-MS system and identified using the known fragmentation pattern and m/z of 
alkylated EGT. Full scan mass spectra identified alkylated EGT again in its double protonated 
form at a retention time of 25.4 min in culture supernatants of BY4741p426 GPD-egtA (Figure 
3.14). Tandem mass spectrometry of m/z 309 revealed the daughter ions m/z 257 and 287 
confirming m/z 309 was indeed alkylated EGT (Figure 3.15). Again m/z 617 and m/z 309 was 
not detected in the culture supernatants of negative control cultures of BY4741p426-GPD. 
 
 
Figure 3.14 Identification of the double protonated form of alkylated EGT (M + H)2+ = 
m/z 309 in BY4741p426-GPD-egtA culture supernatant. Full scan MS of BY4741p426-GPD-egtA 
identified at a retention time of 25.39 min. (A) Alkylated EGT m/z 309 (B) in the culture 
BY4741p426-GPD-egtA at a retention time of 25.39 min. (B) The double protonated form of 
alkylated EGT. 
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Figure 3.15 Tandem mass spectrometry of m/z 309 identifies the daughter ions m/z 287 
and m/z 257 in culture supernatant. MS2 of m/z 309 produced the predicted daughter ions 
of m/z 309 confirming the presence alkylated EGT extracellularly. 
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3.4 Detection of ergothioneine in the yeast S. cerevisiae using RP-HPLC analysis 
 
Alkylation of an EGT standard with 5’-IAF was seen to produce a peak with a 
retention time of approximately 13.7 min to 13.8 min varying slightly with room temperature 
(Figure 3.16), using an Agilent Eclipse XDB-C18 column and a Shimadzu Prominence HPLC 
system as described in Section 2.1.12.1.  
 
 
 
Figure 3.16 Detection of alkylated EGT standard (100 µg/ml) compared to PBS negative 
control. Alkylated EGT elutes from the stationary phase at a retention time of approximately 
13.8 min (black) with no peak in PBS control (red).  
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Extracellular EGT levels were examined by preparing cultures in triplicate at the time 
points 24 h, 48 h, 72 h, 96 h and 120 h. Cell lysates were then prepared and alkylated with 5’-
IAF as described in Section 2.2.9.2 and examined using RP-HPLC analysis as described in 
Section 2.2.9.4. Extracellular EGT was identified in BY4741p426-GPD-egtA culture supernatants 
by comparison with culture supernatant from the negative control BY4741426-GPD. RP-HPLC 
analysis revealed the presence of an additional peak in BY4741p426-GPD-egtA supernatant with 
a retention time of 13.83 matching the retention time of the EGT standard (Figure 3.17).  
 
 
 
 
Figure 3.17 Detection of EGT in BY4741p426-GPD-egtA in culture supernatants using RP-
HPLC analysis. Novel peak identified in alkylated culture supernatants of BY4741p426-GPD-
EgtA (black) when compared to alkylated culture supernatant from BY4741p426-GPD (red) 
matches the retention time of alkylated EGT standard of 13.8 min. 
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Intracellular EGT levels were then investigated, by preparing cultures in triplicate at 
the time points of 24, 48 and 72 h. From these cell lysates were prepared and alkylated with 
5’-IAF as described in Section 2.2.9.1. BY4741p426-GPD-egtA lysates were examined in 
comparison to BY4741p426-GPD for the presence of intracellular EGT. At the time point of 24 
h EGT was identified to be co-eluting with a small peak with a retention time of 13.81 min 
noticed in the control BY4741p426-GPD (Figure 3.18). No EGT was identified in cell lysates 
from 48 h and 72 h cultures. 
 
 
Figure 3.18 EGT in BY4741426-GPD-egtA in cell lysates using RP-HPLC analysis. Peak of 
BY4741p426-GPD-EgtA cell lysate (black) when compared to alkylated cell lysate from 
BY4741p426-GPD (red) which matches the retention time of alkylated EGT (13.8 min). A small 
peak can be seen to co-elute with EGT in cell lysates of BY4741p426-GPD. 
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3.5 Quantification of EGT in the yeast S. cerevisiae using RP-HPLC analysis shows a 
greater abundance of EGT in culture supernatant 
 
A standard curve was constructed as described in Section 2.2.9.3 to enable 
determination of the quantity of EGT in BY4741426-GPD-egtA. EGT was measured in terms of 
the peak area produced by the quantity of EGT loaded onto the column (Figure 3.19). The 
quantity EGT in culture supernatants of 24 h, 48 h, 72 h, 96 h and 120 h BY4741426-GPD-egtA 
cultures was calculated using the standard curve as described in Section 2.2.9.5.  
 
 
 
Figure 3.19 Standard curve of EGT. Standard curve generated using 9 EGT standards 
ranging from 0.08 µg/ml to 20.83 µg/ml of EGT loaded onto column. Accuracy of standards 
was gauged by the curves R2 value which was 0.9998 indicating a high degree of accuracy 
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EGT was quantified using the equation produced from the standard curve as described 
in Section 2.2.9.6. A small amount of intracellular EGT was only detected at 24 h and present 
at a significantly higher level extracellularly at 24 h (P < 0.0001).The quantity of EGT in 
supernatant of BY4741426-GPD-egtA rose at the time points 48 h, 72 h and peaked at 96 h with 
7.93 mg/L of EGT detected (Figure 3.20). This indicates that most EGT is either been effluxed 
out of cells or possibly leaking from cells at death phase as the cell membrane loses its 
integrity.  
 
 
Figure 3.20 Quantification of EGT production (n = 2).  Quantity of EGT in BY4741426-
GPD-egtA grown in SC media. 1= Quantity of intracellular EGT (10.12 µg/L) after 24 h. 2= 
Quantity of extracellular EGT (1.91 mg/L) after 24 h. 3= Quantity of extracellular EGT (4.89 
mg/L) after 48 h. 4= Quantity of extracellular EGT (6.07 mg/L) after 72 h. 5= Quantity of 
extracellular EGT (7.93 mg/L) after 96 h. 6= Quantity of extracellular EGT (7.53 mg/L) after 
120 h. 
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3.6 Phenotypic response of S. cerevisiae ergothioneine producing strain to oxidative 
stress from hydrogen peroxide 
 
 The S. cerevisiae EGT producing strain BY4741426-GPD-egtA was investigated to see if 
production of EGT would increase growth when experiencing oxidative stress from the ROS 
stressor, hydrogen peroxide. However BY4741426-GPD-egtA did not confer any resistance to 
oxidative stress from hydrogen peroxide. BY4741426-GPD-egtA was observed to have increased 
sensitivity to hydrogen peroxide when compared to wildtype BY4741426-GPD at a 
concentration of 1-1.5 mM hydrogen peroxide (Figure 3.21 B and C). Both BY4741426-GPD-
egtA and wildtype growth was abolished at 2 mM hydrogen peroxide (Figure 3.21 D). 
 
Figure 3.21 A-D Growth analysis of S. cerevisiae strains on synthetic complete media 
(SC) with hydrogen peroxide. Comparative growth analysis assay using strains BY4741426-
GPD and BY4741426-GPD-egtA. (A) Strains BY4741426-GPD and BY4741426-GPD-egtA grown on SC 
media. (B) Strains BY4741426-GPD and BY4741426-GPD-egtA grown on SC media with 1 mM 
hydrogen peroxide added. (C) Strains BY4741426-GPD and BY4741426-GPD-egtA grown on SC 
media with 1.5 mM hydrogen peroxide added. (D) Strains BY4741426-GPD and BY4741426-GPD-
egtA grown on SC media with 2 mM hydrogen peroxide added. 
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BY4741426 GPD-egtA did not confer any additional tolerance to ethanol, growth was 
maintained at wildtype level and abrogated completely at a concentration of 8 % ethanol 
(Figure 3.22).  
 
 
Figure 3.22 A-D Growth analysis of S. cerevisiae strains on synthetic complete media 
(SC) with ethanol. (A) Strains BY4741426-GPD and BY4741426-GPD-egtA grown on SC media. 
(B) Strains BY4741426-GPD and BY4741426-GPD-egtA grown on SC media with 4 % ethanol 
added. (C) Strains BY4741426-GPD and BY4741426-GPD-egtA grown on SC media with 8 % 
ethanol added. 
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3.7 BY4741426-GPD-egtA egtA mutant T213A shows increased production of EGT at 24 h 
but is not significant.  
 
Phosphate-based signalling is critical to almost all major cellular processes and is 
ubiquitously present across Archaea, Prokaryotes, and Eukaryotes (Kannan et al., 2007). 
EgtD in M. tuberculosis was identified to be negatively regulated by phosphorylation at Thr213 
by PknD a serine protein kinase (Richard-Greenblatt et al., 2015). The S. cerevisiae genome 
is predicted to contain 122 protein kinases (Zhu et al., 2000). With the exception of two 
histidine protein kinases all of the yeast protein kinases are members of the Ser/Thr family 
(Zhu et al., 2000). Thr213 was identified to be conserved in EgtA and was reasoned that it 
could be indiscriminately phosphorylated in S. cerevisiae. To investigate this site directed 
mutagenesis was used to changing Thr213 to Ala as described in Section 2.2.2.2. Conversion 
of Thr213 to Ala was confirmed by DNA sequence analysis as described in Section 2.2.2.3. 
The p426 GDP-EgtA T213A mutant was transformed into S. cerevisiae BY4741 and selected 
by their ability to grow on –URA SC media as well as carrying out a colony PCR (Figure 
3.23). 
 
 
         
Figure 3.23 Presence of egtA T213A confirmed in BY4741 by colony PCR. Lane 1= 10 kb 
NEB DNA ladder, lanes 2 & 3= egtA T213A in BY4741 p426-GPD-egtA T213A (size 2.5 kb) 
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amplified with high fidelity Taq, lane 4 empty, lane 5= negative control, lane 6= positive 
control p423-GPD-egtA (size 2.5 kb). 
RP-HPLC analysis determined BY4741 p426-GPD-egtA T213A produces EGT by 
identification of a peak at 13.84 min with an identical retention time to an EGT standard 
(Figure 3.24 A-B). This peak was present in both cell lysates and culture supernatant of 
BY4741 p426-GPD-egtA T213A and was not present in the control strain BY4741 p426-GPD at the time 
point of 24 h (Figure 3.24 C-D). 
 
 
Figure 3.24 A-D EGT production by BY4741 p426-GPD-egtA T213A. (A) Extracellular EGT 
detected in culture supernatant (black) by seeing a peak at a retention time of 13.84 min 
compared to an EGT peak in an EGT standard, 13.84 min (red). (B) Intracellular EGT detected 
in cell lysate with a retention time of 13.84 min detected (black) compared to EGT standard, 
13.84 min (red). (C) Extracellular EGT detected in culture supernatants. BY4741 p426-GPD-egtA 
T213A produces EGT seen by a peak at 13.85 min (black) compared to BY4741 p426-GPD (red) 
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which does not produce EGT. (D) Intracellular EGT detected in cell lysates. BY4741 p426-GPD-
egtA T213A produces EGT seen by a peak at 13.84 min (black) compared to BY4741 p426-GPD 
(red) which does not produce EGT. 
In triplicate 24 h cultures of BY4741 p426-GPD-egtA T213A were shown to have higher 
levels of EGT than BY4741 p426-GPD-egtA both extracellularly and intracellularly at 24 h but this 
was not statistically significant (Figure 3.25 A & B).  However this trend was reversed in 72 
h cultures with the extracellular EGT level of BY4741 p426-GPD-egtA T213A lower than that of 
BY4741 p426-GPD-egtA (Figure 3.25 C). Overall there was an increase in extracellular EGT in 72 
h cultures of BY4741 p426-GPD-egtA T213A and BY4741 p426-GPD-egtA compared to their 24 h 
counterparts in keeping with previous observations.  
 
 
Figure 3.25 A-C Comparison of EGT production in BY4741 p426-GPD-egtA T213A to BY4741 
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p426-GPD-egtA (n = 2).  (A) Peak areas of 24 h extracellular EGT in BY4741 p426-GPD-egtA T213A and 
BY4741 p426-GPD-egtA. (B) Peak areas of 24 h intracellular EGT in BY4741 p426-GPD-egtA T213A and 
BY4741 p426-GPD-egtA. (C) Peak areas of 72 h extracellular EGT in BY4741 p426-GPD-egtA T213A 
and BY4741 p426-GPD-egtA. 
3.8 Co-expression of egtA with the egtB candidate AFUA_2G13295 decreases the level 
of EGT in S. cerevisiae.  
 
 The egtB candidates AFUA_2G13295 (egt2a) and AFUA_3G14240 (egt2b) were 
selected due to their sequence homology with known cysteine desulfurases used in the EGT 
biosynthetic pathway.  Egt2a is a possible homologue of the cysteine desulfurase gene 
SPBC660.12c determined to be egt2 in S. pombe by Pluskal et al. (2014) sharing 29 % 
identity. Egt2a  shares homology with mycobacterial EgtE as well as Egt2 identified in N. 
crassa sharing 45 % identity with N. crassa Egt2 (Bello et al. (2012). Egt2b is a mitochondrial 
cysteine desulfurase and a homologue of nfs1 found in S. cerevisiae which we considered the 
enzyme most likely to be completing EGT biosynthesis in S. cerevisiae. 
 RNA was extracted from the A. fumigatus strain AF293 as described in Section 2.2.6.1 
and reverse transcribed into cDNA as described in Section 2.2.6.4.  Egt2a and  egt2b were 
amplified from cDNA by PCR using high fidelity Taq with proof reading ability to ensure 
sequence integrity. Egt2a was amplified using the primer set egt2a F and egt2a R (Figure 3.26 
A), for AFUA_3G14240 the primer set egt2bF and egt2b R (Figure 3.26 B) as described in 
Table 2.3. Cloning of both  egt2a and  egt2b used the cloning strategy Spe1 and EcoR1 at the 
5’ and 3’ end respectively. 
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Figure 3.26 A-B Amplification of egt2a and egt2b from AF293 cDNA. (A) Lane 1= 10 kb 
NEB DNA ladder, lanes 2 & 3= egt2a (size 1.3 kb), lane 4= negative control. (B) Lane 1= 10 
kb NEB DNA ladder, lane 2= empty, lanes 3 & 4= egt2b (size 1.55 kb), lane 5= negative 
control. 
 
 
The PCR products of egt2a and egt2b were cleaned using Qiagen PCR purification kit 
as per manufacturer’s instructions prior to use. The cleaned PCR products were then digested 
to create the sticky ends, required when ligating the egtA insert. The vector p423-ADH (Figure 
3.27), was also digested in preparation for ligation.  
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Figure 3.27 The 7.6 kb episomal S. cerevisiae shuttle vector p423 ADH used to express 
recombinant egt2a and egt2b. An AmpR gene for selection after cloning into E. coli is 
present along with a HIS3 gene for selection after transformation into S. cerevisiae and the 
restriction enzyme sites Spe1 and EcoR1 used as part of the cloning strategy. 
 
Both inserts and vector were digested with the restriction enzymes Spe1 and EcoR1 
for 3 h at 37 °C and separated using gel electrophoresis on an agarose gel (Figure 3.28 A, B 
& C).  Fragments were then excised from the agarose gel using Qiagen quick gel extraction 
kit as per manufacturer’s instructions. 
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Figure 3.28 A-C Digestion of egt2a, egt2b and p423 ADH with the restriction enzymes 
Spe1 and EcoR1. Lane 1= 10 kb NEB DNA ladder, (A) lane 2= empty, lanes 3 & 4= digest 
of egt2a (size 1.3 kb), (B) Lane 2= empty, lanes 3 = Digest of egt2b (size 1.55 kb), (C) Lanes 
2 & 3= digest of p426 GPD (size 7.6 kb). 
 
 
After gel extraction of digested inserts and vector the DNA concentration of samples 
was measured using a Nanodrop (Mason). The egt2a and egt2b inserts were then ligated 
separately into the vector p423-ADH as described in Section 2.2.3.5 and left overnight at 16 
°C. The ligation products p423-ADH-egt2a and p423-ADH-egt2b were then transformed into 
E. coli cells as described in Section 2.2.4.5. E. coli cells with p423 ADH-egt2a and p423 
ADH-egt2b were selected by their ability to grow on LB-amp-agar plates. P423-ADH-egt2a 
and p423-ADH-egt2b plasmid DNA was purified from transformed E. coli as described in 
Section 2.2.5.1.  P423-ADH-egt2a and p423-ADH-egt2b plasmid DNA was then transformed 
into the S. cerevisiae strain BY4741p426-GPD-egtA as described in Section 2.2.4.2. An empty 
p423-ADH plasmid was transformed into BY4741p426-GPD-egtA for a better comparison. 
Successful transformants were selected by their ability to grow on –URA -HIS SC media. A 
colony PCR was carried out on selected colonies to further confirm that the transformation 
was a success (Figure 3.29).  
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Figure 3.29 Successful transformation of egt2a and egt2b into BY4741p426-GPD-egtA 
confirmed by colony PCR. (A) Lane 1= 10 kb NEB DNA ladder, lanes 2-8 = egt2a (size 1.3 
kb) from S. cerevisiae BY4741p426-GPD-egtA p423 ADH-egt2a amplified with high fidelity taq, lane 
9= positive control egt2a (size 1.3 kb) from p423-ADH-egt2a, lane 10= negative control. (B) 
Lane 1= 10 kb NEB DNA ladder, lanes 2-8 = egt2b (size 1.55 kb) from S. cerevisiae 
BY4741p426-GPD-egtA p423-ADH-egt2b amplified with high fidelity Taq, lane 9= positive control 
egt2b (size 1.55 kb) from p423-ADH-egt2b, lane 10= negative control. 
  
 Expression of egt2a was confirmed by generation of a His tag on the N-terminus of 
Egt2a in the vector p423-ADH. The same method was employed as in Section 3.3 using the 
appropriate primers listed in Table 2.3 and the template p423-ADH using the restriction sites 
Spe1 and Xho1 at the 5’ and 3’ end respectively. Following a successful transformation of 
BY4741 with 423 ADH-egt2a and 423-ADH-egt2b with an N terminal His tag successful 
transformants were screened by colony PCR as in Section 3.3. A western blot was preformed 
to confirm expression of egt2a and egt2b.  Cultures of BY4741 423-ADH-egt2a His tag and BY4741 
423 ADH-egt2b His tag were grown for 24 h cell lysates and loaded onto a polyacrylamide gel and 
transferred onto a PVDF membrane. Egt2a was shown to be transcribed and expressed by 
BY4741 423-ADH-egt2a His tag (Figure 3.30). Unfortunately expression of Egt2b could not be 
detected when either an N- or C-terminal His tag was used. 
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Figure 3.30 Western Blot confirming the expression of Egt2a in BY4741p423-ADH-egt2a His 
tag. Lane 1= NEB Prestained Protein ladder 175-7 kDa, lanes 2-3= Egt2a His tag protein (50 
kDa) from S. cerevisiae BY4741426 GPD-egt2a His tag cell lysate, lanes 6-7= negative control 
BY4741426-GPD-egt2a cell lysate. 
 
 
 EGT production was compared by looking at the peak area of EGT detected in culture 
supernatants as quantification of EGT had shown a greater abundance of EGT extracellularly 
(Section 3.5). EGT was confirmed to be produced in BY4741p426-GPD-egtA p423-ADH-egt2a (Figure 
3.31 A-B).  
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Figure 3.31 Confirmation of EGT production in BY4741p426-GPD-egtA p423-ADH-egt2a. (A) EGT 
in BY4741p426-GPD-egtA p423-ADH-egt2a at a retention time of 13.84 min (black) compared to the 
EGT standard 13.85 min (red). (B) EGT in BY4741p426-GPD-egtA p423-ADH-egt2a at a retention time 
of 13.84 min (black) compared to the BY4741p426-GPD p423 ADH no EGT is produced. 
 
 
 
 
Surprisingly there was significantly less extracellular EGT detected in BY4741p426-
GPD-egtA p423-ADH-egt2a when compared with BY4741p426-GPD-egtA p423 ADH at 48 h and 72 h (Figure 
3.32 A-B).  
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Figure 3.32 Significantly less extracellular EGT produced in BY4741p426-GPD-egtA p423-ADH-
egt2a compared to BY4741p426-GPD-egtA p423-ADH (n = 2).  (A) Peak areas of EGT in the 
supernatant of cultures grown for 48 h showing significantly higher levels (P = 0.0063) of 
EGT in BY4741p426-GPD-egtA p423 ADH compared to BY4741p426-GPD-egtA p423-ADH-egt2a. (B) Peak 
areas of EGT in the supernatant of cultures grown for 72 h showing significantly higher levels 
(P = 0.0018) of EGT in BY4741p426-GPD-egtA p423 ADH compared to BY4741p426-GPD-egtA p423-ADH-
egt2a. 
 
3.9 Reduction in expression of yeast nfs1 or S-adenosyl-L-homocysteine hydrolase does 
not reduce production of EGT in S. cerevisiae 
Native S. cerevisiae nfs1 (nfs1) involvement in EGT biosynthesis was investigated. 
Yeast nfs1 shares homology with both egt2a sharing 23 % identity, egt2b in particular shares 
a high degree of similarity (70 % identity). The strain R1158Tet nfs1 (derived from BY4741) 
was purchased from Dharmacon with ScNFS1 expression regulated by a TET off system by 
replacement of the native promoter with a CMV promoter and tta gene. Addition of 
doxycycline in a titratable manner allows for down-regulation of the promoter until the gene 
of interest is no longer expressed at detectable levels 
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(http://dharmacon.gelifesciences.com/non-mammalian-cdna-and-orf/yeast-tet-promoters-
collection/).  
S-adenosyl-L-homocysteine hydrolase (SAHH) is required in the metabolic pathway 
of sulphur-containing amino acids (Ulrey et al., 2005). SAHH plays an essential cellular role 
catalysing the breakdown of S-adenosyl-L-homocysteine (SAH) by catalysing the reversible 
hydrolysis of SAH into adenosine and homocysteine (Altintas & Sezgin 2004). This allows 
for homocysteine to undergo irreversible trans-sulfurization catalysed by pyridoxal phosphate 
containing enzymes to form cysteine or is converted back to methionine by the addition of a 
methyl group catalysed by methionine synthase (Altintas & Sezgin 2004).  A methyl group 
from methionine becomes activated by adenosine triphosphate (ATP) with the addition of an 
adenosine to its methyl group to produce the universal methyl donor S-adenosyl methionine 
(SAM) (Boison 2013). Once the methyl group is removed from SAM it becomes SAH 
concluding the cycle (Figure 3.33). 
 
  
 
Figure 3.33 The methionine cycle. SAM the methyl donor to various methyltransferases 
such as EgtD, SAH formed from the removal of the methyl group from SAM which is 
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immediately broken down into adenosine and homocysteine catalysed by SAHH. Adapted 
from Boison (2013). 
 
Seebeck (2010), identified SAM as the methyl donor in the reaction catalysed by 
mycobacterial EgtD a methyltransferase which tri-methylate’s histidine to form hercynine. 
Elevated SAH levels, consequent to Hercynine biosynthesis, could inhibit the His tri-
methylation reaction. Thus expression of S. cerevisiae SAHH was investigated for its affect 
on EGT production by regulation of SAHH expression through the TET off system. The strain 
R1158Tet SAHH (derived from BY4741) was purchased from Dharmacon with the native S. 
cerevisiae SAHH promoter replaced with a CMV promoter controlled by the tet trans-
activator protein. Both R1158Tet nfs1 and R1158Tet SAHH contain the ura3 marker preventing 
transformation of the p423-egtA which also contains the ura3 marker. The plasmid p423-GPD 
(Figure 3.34 A) was chosen instead containing a his3 marker and digested with Spe1 and Xho1 
using the same cloning strategy as described in Section 3.2 (Figure 3.34 B).  
 
 
 
Figure 3.34 A & B Digest of the plasmid p423 GPD. (A) Lane 1= 10 kb NEB DNA ladder, 
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lanes 2 & 3= digested p423 GPD (size 5.9 kb). (B) Map of p423 GPD with the restriction 
sites Spe1 and Xho1 highlighted. 
 
 
p423-GPD-egtA was ligated and transformed into E. coli cells and selected by their 
ability to grow on LB-amp-agar plates. P423-GPD-egtA was purified from E. coli containing 
p423-GPD-egtA as described in Section 2.2.5.1.  P423-GPD-egtA plasmid DNA was then 
transformed into the S. cerevisiae strains R1158Tet Nfs1 and R1158Tet SAHH as described in 
Section 2.2.4.2. Successful transformants were selected by their ability to grow on –Ura SC 
media. A colony PCR was also carried out on selected colonies of R1158Tet Nfs1 p423-GPD-egtA 
and R1158Tet SAHH p423-GPD-egtA to confirm EgtA was present (Figure 3.32 A-B). 
 
 
Figure 3.32A-B Colony PCR of R1158Tet Nfs1 p423-GPD-egtA and R1158Tet SAHH p423-GPD-egtA 
confirming the presence of the egtA gene. (A) Lane 1= 10 kb NEB DNA ladder, lanes 2-4= 
egtA R1158Tet Nfs1 p423-GPD-egtA (size 2.5 kb), lane 4= negative control, lanes 5-8 empty. (B) 
Lane 1= 10 kb NEB DNA ladder, lanes 2-7= egtA R1158Tet SAHH p423-GPD-egtA (size 2.5 kb), lane 
8= positive control p423-GPD-egtA (size 2.5 kb). 
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EGT was confirmed to be produced by both strains R1158Tet Nfs1 p423-GPD-egtA and 
R1158Tet SAHH p423-GPD-egtA using RP-HPLC analysis by comparison with an EGT standard and 
negative control (Figure 3.33A-D) 
 
Figure 3.33 A-D EGT production identified in R1158Tet Nfs1 p423-GPD-egtA and R1158Tet SAHH 
p423-GPD-egtA. (A) EGT in R1158Tet NFS1 p423-GPD-egtA at a retention time of 13.83 min (black) 
compared to the EGT standard 13.84 min (red). (B) EGT in R1158Tet Nfs1 p423-GPD-egtA at a 
retention time of 13.83 m (black) compared to the negative control R1158Tet Nfs1 p423-GPD no 
EGT is produced. (C) EGT standard 13.9 min (red) analysed with R1158Tet Nfs1 p423-GPD-egtA but 
produced to large a peak to show on the same graph. (D) EGT in R1158Tet Nfs1 p423-GPD-egtA at a 
retention time of 13.9 min (black) compared to the negative control R1158Tet Nfs1 p423-GPD no 
EGT is produced. 
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Repression of nfs1 and SAHH in the strains R1158Tet Nfs1 p423-GPD-egtA and R1158Tet SAHH 
p423-GPD-egtA were assessed by examining each strains growth in the presence of varying 
concentrations of doxycycline in SC –His, -Ura agar. Addition of doxycycline caused reduced 
expression of Nfs1 and SAHH which was observed as the concentration of doxycycline 
gradually increased causing down regulation of the promoter until either Nfs1 or SAHH was 
no longer expressed. Both nfs1 and SAHH are essential for growth, allowing repression of 
nfs1 and SAHH to be visualized by observing the growth of R1158Tet Nfs1 p423-GPD-egtA and 
R1158Tet SAHH p423-GPD-egtA in comparison to the control strain BY4741 p423-GPD (Figure 3.34 A-
F). Growth of R1158Tet Nfs1 p423-GPD-egtA decreased as doxycycline levels increased however a 
higher concentration of doxycycline was required in comparison to R1158Tet SAHH p423-GPD-egtA 
which was sensitive after as little as 0.5 µg/ml of doxycycline was added (Figure 3.34 A-D).  
Growth analysis of R1158Tet Nfs1 p423-GPD-egtA in the presence of doxycycline showed 
that a higher quantity of 100-150 µg/ml was required to slow growth without adversely 
affecting BY4741 p423-GPD (Figure 3.34 E-F). Growth analysis of R1158Tet SAHH p423-GPD-egtA 
demonstrated that a concentration range of (0.5 to 10 µg/ml was sufficient to induce a 
gradually diminished growth rate dependant on the doxycycline concentration. 
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Figure 3.34 A-D Growth analysis of S. cerevisiae strains on synthetic complete media 
(SC) with doxycycline after 72 h. (A) Strains R1158Tet SAHH p423-GPD-egtA, R1158Tet Nfs1 p423-
GPD-egtA and BY474 p423-GPD grown on SC media. (B) Strains R1158Tet SAHH p423-GPD-egtA, 
R1158Tet Nfs1 p423-GPD-egtA and BY4741426-GPD grown on SC media with 0.5 µg/ml of 
doxycycline added. (C) Strains R1158Tet SAHH p423-GPD-egtA, R1158Tet Nfs1 p423-GPD-egtA and 
BY4741p423-GPD grown on SC media with 4 µg/ml of doxycycline added. (E) Strains R1158Tet 
SAHH p423-GPD-egtA, R1158Tet Nfs1 p423-GPD-egtA and BY4741p423-GPD grown on SC media with 8 
µg/ml of doxycycline added. (D) Strains R1158Tet SAHH p423-GPD-egtA, R1158Tet Nfs1 p423-GPD-egtA 
and BY4741p423-GPD grown on SC media with 100 µg/ml of doxycycline added. (F) Strains 
R1158Tet SAHH p423-GPD-egtA, R1158Tet Nfs1 p423-GPD-egtA and BY4741p423-GPD grown on SC media 
with 150 µg/ml of doxycycline added. 
 
Cultures of R1158Tet SAHH p423-GPD-egtA were grown for 72 h in various concentrations 
of doxycycline which was determined by analysis of growth assays (Figure 3.34). RP-HPLC 
analysis of extracellular EGT levels in R1158Tet SAHH p423-GPD-egtA culture supernatant showed 
a significant decrease (P = 0.0281) of EGT levels in culture supernatant with a doxycycline 
concentration of 4 µg/ml and a significant (P = 0.0049) decrease of EGT levels in culture 
supernatant with a doxycycline concentration of 0.5 µg/ml (Figure 3.35 A). Cultures grown 
with a doxycycline concentration of 1, 2, 5 and 10 ug/ml all shown a decrease of EGT levels 
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in culture supernatant but was not statistically significant (Figure 3.35 B). This data suggests 
SAHH activity is required to prevent elevated SAH levels causing inhibition of EGT 
biosynthesis, via attenuation of methyltransferase activity of EgtA. 
Figure 3.35 Repression of SAHH in R1158Tet SAHH p423-GPD-egtA decreases the level of EGT 
in 72 h cultures (n = 2). (A) Peak area of EGT in R1158Tet SAHH p423-GPD-egtA grown in SC 
media and with various concentrations of doxycycline. 1= 4 µg/ml of doxycycline added 
(Peak Area 141286). 2= 0.5 µg/ml of doxycycline added (Peak Area 209633). 3= No 
doxycycline added (Peak Area 168898). (B) 1= 1 µg/ml of doxycycline added (Peak Area 
171599). 2= 2 µg/ml of doxycycline added (Peak Area 189819). 3= 5 µg/ml of doxycycline 
added (Peak Area 197559). 4= 10 µg/ml of doxycycline added (Peak Area 187732). 5= No 
doxycycline added (Peak Area 209633).  
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Cultures of R1158Tet nfs1 p423-GPD-egtA were grown for 72 h in 100 and 150 µg/ml doxycycline 
which was determined by analysis of growth assays. RP-HPLC analysis of extracellular EGT 
levels in R1158Tet nfs1 p423-GPD-egtA culture supernatant shown an increase in EGT levels of 
culture supernatants grown with a doxycycline when compared to R1158Tet nfs1 p423-GPD-egtA 
grown without doxycycline. This increase was statistically significant (P = 0.0353) at a 
concentration of 100 ug/ml (Figure 3.36). 
Figure 3.36 Repression of nfs1 in R1158Tet Nfs1 p423-GPD-egtA increases the level of EGT in 
72 h cultures (n = 2).  (A) Peak area of EGT in R1158Tet nfs1 p423-GPD-egtA grown in SC media 
and various levels of doxycycline. 1= 100 µg/ml of doxycycline added (Peak Area 132369). 
2= 150 µg/ml of doxycycline added (Peak Area 217091). 3= No doxycycline added (Peak 
Area 168898).  
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4.1 Discussion 
EGT is an important NP which has potential uses in biotechnology, the cosmetics 
industry and the food industry as a preservative (Bao et al., 2010). EGT has been previously 
shown to demonstrate interesting biochemical properties such as antioxidant capabilities 
(Cheah & Halliwell, 2012). Identification of a putative EGT transporter OCTN1 expressed 
highly on the membranes of mammalian cells as well as on the membrane of mitochondria 
suggests EGT is an important biomolecule that may act as a cytoprotective (Halliwell et al., 
2016; Gründemann, 2012; Paul & Snyder, 2009).  
This body of work shows how transformation of the gene egtA from the saprotrophic 
fungus A. fumigatus into the S. cerevisiae strain BY4741 using an episomal vector, enables 
the de novo production of EGT. Expression of the A. fumigatus protein EgtA was confirmed 
by protein mass spectrometry and production of EGT was confirmed by both RP-HPLC and 
LC-MS analysis. By quantifying the level of EGT intracellularly and extracellularly, it was 
revealed that EGT builds up in the culture supernatant at far more significant level compared 
to the level of EGT seen in yeast cell lysates. EGT was seen to accumulate over time in the 
culture supernatant until the time point of 96 h was reached using a batch fermentation model 
making S. cerevisiae ideal for the production of EGT. 
To further understand how EGT was being produced by the protein EgtA in A. 
fumigatus and S. cerevisiae proteins were identified that shared homology with other cysteine 
desulfurase identified to be involved in EGT biosynthesis (Qin et al., 2014; Pluskal et al., 
2014). Co-expression of EgtA with AFUA_2G13295 (Egt2a) caused a significant decrease in 
EGT production S. cerevisiae. Interestingly decreasing the expression of the yeast Nfs1 a 
native cysteine desulfurase in S. cerevisiae caused an increase in EGT levels. This indicates 
EGT production by EgtA may be somehow affected by the cysteine desulfurase shown to be 
required to complete EGT biosynthesis (Seebeck, 2010; Qin et al., 2014; Pluskal et al., 2014). 
 Mutation of a conserved residue in EgtA known to be involved in the negative 
regulation of EGT production in M. tuberculosis showed this residue might also be 
phosphorylated in S. cerevisiae as EGT levels were seen to increase when Thr213 was changed 
to Ala. This work suggests that with further knowledge of EGT biosynthesis in A. fumigatus 
and genetic manipulation of the protein EgtA, S. cerevisiae can be used as a cellular factory 
for commercially viable production of EGT. 
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The gene AFUA_2G15650 from A. fumigatus was identified to be involved in 
production of EGT. Expression of recombinant EgtA in S. cerevisiae was determined to 
produce EGT by detection of alkylated EGT using RP-HPLC analysis. Alkylation of EGT 
with 5’-IAF and analysis using RP-HPLC first deployed by (Gallagher et al., (2012) has been 
shown to be an accurate and sensitive way of quantifying EGT. In this study a minimum of 
51.58 µmol/L of EGT was detected in the production of an EGT standard curve however 
Sotgia et al., (2013) have used a similar method to detect as little as 0.15 µmol/L. Other 
derivatization agents have also been used to alkylate EGT such as 7-diethylamino-3-[4-
(iodoacetamido) phenyl]-4-methylcoumarin which was shown to detect EGT at 0.10 µmol/L 
using HPLC analysis (Sotgia et al., 2014).  
In recombinant S. cerevisiae, EGT was only detected intracellularly at 24 h and 
identified to be present at a significantly higher level extracellularly in 24 h cultures (P 
<0.0001) with 99.5 % of EGT in the culture supernatant of BY4741p426-GPD-egtA. Larger 
quantities of EGT were seen to be present in 48 h and 72 h cultures and continued to rise 
peaking in the culture supernatant of 96 h cultures with 7.93 mg/L of EGT detected. This is 
not as large as the quantity of intracellular EGT detected by Pluskal et al., (2014) who 
managed to produce 266.3 mg/L of EGT detected in a Schizosaccharomyces pombe Egt-1 
overexpression strain in a 20 day fermentation where the culture media was replaced with 
fresh media every 6-7 days. A longer term continuous fermentation would need to be carried 
out to confirm that BY4741p426-GPD-egtA could produce similar quantities of EGT. However, 
production of EGT in S. cerevisiae offers several advantages such as its extensive track record 
for expressing recombinant protein (Da Silva & Srikrishnan 2012). Another major advantage 
is how the vast majority of EGT being present in the culture supernatant. This allows for an 
easier extraction of EGT compared to extraction of EGT from intracellular sources and is 
more ideal for use in a continuous fermentation system. 
Phenotypic analysis was conducted to determine if EGT increased the antioxidant 
capacity of S. cerevisiae to deal with oxidative agents such as hydrogen peroxide. BY4741p426-
GPD-egtA exposed to increasing concentrations of the oxidant hydrogen peroxide was shown to 
have impaired growth compared to the control strain BY4741p426-GPD. This was not 
completely unsurprising to see EGT production not increase the antioxidant capabilities of S. 
cerevisiae as a similar result had been seen by the fission yeast S. pombe by Pluskal et al., 
(2014). Here an egt-1 overexpression strain producing greater quantities of  EGT compared 
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to the wildtype strain showed no increased resistance to hydrogen peroxide or tert-butyl 
hydrogen peroxide seen by Bello et al., (2012) to cause sensitivity in the N. crassa egt-1 
deletion strain. 
It may be that EGT acts as a supplementary antioxidant or has a highly specialized 
cellular function as suggested by Halliwell et al., (2016) such as involvement in tissue repair. 
Fungi and Bacteria that produce EGT also produce other antioxidants which have been 
demonstrated to have more effective antioxidant capabilities against a broad range of free 
radicals. An example of this would be the production of MSH the primary antioxidant of 
Mycobacteria (Rawat et al., 2002). Mutants of M. tuberculosis which cannot produce MSH 
or EGT have been characterised to have reduced antioxidant capabilities and greater 
sensitivity towards antibiotics such as erythromycin or rifampicin however MSH deficient 
strains have demonstrated a greater amount of sensitivity (Saini et al., 2015; Greenblatt et al., 
2015).  
The most likely reason for impaired growth in BY4741p426-GPD-egtA whilst under 
increased oxidative stress is the increased strain put on S. cerevisiae producing EGT under a 
constituent promoter and a high output origin of replication (2µ). S. cerevisiae already has a  
stable redox homeostasis mediated by production of high levels of GSH and enzymes such as 
superoxide dismutase and does not seem to require EGT (Steinman, 1980; Grant et al., 1996; 
Lu, 2013). This would also explain why S. cerevisiae does not produce EGT with all other 
fungal phyla identified as having an egtA homologue except for the Saccharomycotina sub-
phylum (Jones et al., 2014). One cannot exclude the possibility that EGT biosynthesis in S. 
cerevisiae interferes with trans-sulfurization systems, and dissipates homocysteine levels by 
prioritization of SAM biosynthesis over provision of Cys for the formation of GSH. Levels 
of Cys for GSH biosynthesis may also be reduced by EGT biosynthesis (Figure 4.1). 
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Figure 4.1 Production of EGT may interfere with GSH production in S. cerevisiae. 
Production of EGT may dissipate homocysteine levels by prioritizing SAM production. 
Cysteine may also be used for production of EGT instead of GSH. Adapted from Manzanares-
miralles et al. (2016). 
 
EgtA was investigated to determine whether phosphorylation of the conserved residue 
Thr213 might be causing down-regulation of EgtA activity as observed by Greenblatt et al., 
(2015) in M. tuberculosis. A single base pair was mutated causing a change in the amino acid 
sequence (T213A) in BY4741p426-GPD-egtA T213A. Cultures (24 h) of BY4741p426-GPD-egtA T213A 
which could no longer be phosphorylated showed an increased level of intracellular and 
extracellular EGT when compared to BY4741p426-GPD-egtA at a time point of 24 h but was not 
statistically significantly higher. This indicates that indiscriminate phosphorylation of Thr213 
as seen in the egtA homologue egtD in M. tuberculosis is a possibility considering the array 
of protein kinases specifically Ser/Thr kinases S. cerevisiae (>122) (Zhu et al., 2000; 
Greenblatt et al., (2015). However examination of 72 h extracellular EGT levels showed a 
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discontinuation of this trend with BY4741p426-GPD-egtA containing a higher level of EGT 
compared to BY4741p426-GPD-egtA T213A. This may indicate that indiscriminate phosphorylation 
may be more likely to occur in higher nutrient conditions such as those present in 24 h cultures 
as opposed to 72 h cultures whose cells have become quiescent due to less metabolic activity. 
Co-expression of EgtA with Egt2a from A. fumigatus thought to be the cysteine 
desulfurase involved in the EGT biosynthetic pathway did not increase the level of EGT 
produced but significantly decreased it. It was observed in 48 h and 72 h culture supernatants 
of BY4741p426-GPD-egtA p423-ADH-egt2a that considerably less EGT was present when compared to 
the strain BY4741p426 GPD-egtA p423 ADH. No EGT was detected in 24 h cultures. This surprising 
result indicates that expression of Egt2a interferes significantly with EGT production in S. 
cerevisiae. Even though a cysteine desulfurase has been shown to be required for EGT 
biosynthesis in both variations of the EGT biosynthetic process too much appears to effect 
EGT production in a negative manner. Another candidate AFUA_3G14240 (Egt2b) a 
homologue to the yeast cysteine desulfurase Nfs1 was investigated but transcription of Egt2b 
with a 6 X histidine tag at the N- or C-terminal end could not be detected by western blot 
analysis leading to the conclusion it could not be expressed in S. cerevisiae. 
BLAST analysis of EgtA shown homology with 32 % identity with S. pombe Egt-1 
(SPBC1604) and 49 % identity with N. crassa Egt-1 (NCU04343) were identical to EgtA. 
Domain analysis shown EgtA does not contain any additional domains that could carry out 
desulfurase activity (Figure 3.1). EGT biosynthesis in Mycobacteria, N. crassa and S. pombe 
have all shown the requirement of a cysteine desulfurase to complete EGT biosynthesis. Since 
expression of A. fumigatus EgtA alone in S. cerevisiae was capable of producing EGT a native 
protein was believed to be catalysing the desulfurization of cysteine. BLAST analysis 
confirmed no homologue of Egt2a was present in S. cerevisiae however a homologue of the 
A. fumigatus cysteine desulfurase Egt2b denoted as Nfs1 was present. Nfs1 in S. cerevisiae 
was therefore deemed to be the most likely candidate to be carrying out the desulfurization of 
cysteine from hercynyl cysteine sulfoxide.  
Repression of yeast Nfs1 using a Tet off system did not cause a decrease in EGT as 
expected but a gradual increase instead which was statistically significant (P < 0.05). This is 
interesting as co-expression of the cysteine desulfurase candidate Egt2a was expected to 
increase or maintain EGT levels but instead was seen to cause a significant decrease (P < 
0.005) in EGT. These results further suggest that cysteine desulfurase, although required to 
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produce EGT, also may act as a negative factor of EGT production (Figure 4.2 A & B). This 
result is also interesting as yeast Nfs1 has been shown to be located mainly inside the 
mitochondrial inner membrane and only low amounts have been reported in the nucleus and 
cytosol (Kispal et al., 1999). This low amount of Nfs1 in the cytosol may actually be providing 
the perfect level of Nfs1 for EGT production when produced under its native promoter 
(Muhlenhoff et al., 2004). 
 
       
Figure 4.2 A & B Effects of cysteine desulfurase expression on EGT production. (A) 
Expression of the A. fumigatus cysteine desulfurase Egt2a caused a decrease in EGT 
production in S. cerevisiae. (B) Decreased expression of native yeast cysteine desulfurase 
Nfs1 using a TET off system was shown to increase EGT production.  
Repression of SAHH was seen to cause a decrease in EGT levels which was 
significant (P = 0.0049) when repressed with a low level of doxycycline 0.5 µg/ml and 
significant (P = 0.0281) when repressed with 4 µg/ml. However no trend was evident 
correlating SAHH repression with a decrease in EGT as 1 and 2 µg/ml of doxycycline did 
show a decrease of EGT levels in culture supernatant but was not statistically significant. This 
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suggests a decrease in SAHH expression does negatively affects EGT production most likely 
by EGTA tri-methyltransferase inhibition or by somehow causing a lack of the methyl donor 
S-adenosyl methionine (SAM) required for the methylation of histidine by EgtA and would 
need to be monitored in any future system used to produce EGT. 
The production of EGT in S. cerevisiae highlights the potential of using yeast as a 
cellular factory for the production of nutritional or industrial important natural products. S. 
cerevisiae showed no toxicity in producing such large amounts of EGT and its secretion of 
EGT makes it ideal for the use of a continuous fermentation system for the production of EGT 
which may allow it to become commercially viable way to produce EGT. This work also 
shows the need for a greater in vivo understanding of the function of EGT. Although EGT has 
been demonstrated to have antioxidant and cytoprotective properties in other fugal species 
this is not conclusive and stresses the need for EGT to be investigated further.  
In an attempt to identify the cysteine desulfurase enzyme required to complete EGT 
biosynthesis in A. fumigatus co-expression of Egt2a with EgtA was shown to significantly 
reduce EGT levels. This indicates production of EGT by EgtA may be hindered if too large a 
quantity of the cysteine desulfurase is present and may be a way of regulating EGT production 
in A. fumigatus. This was again elucidated to when reduced expression of the yeast cysteine 
desulfurase Nfs1 caused an increase in EGT levels. 
Alteration of the expression of the enzymes Nfs1 and SAH hydrolase have been shown 
to have a positive and negative effect on EGT production. Modifications to EgtA has also 
been shown to have an impact on EGT production by changing the conserved residue Thr213 
to Ala suggesting indiscriminate phosphorylation of EgtA may occur in S. cerevisiae. This 
indicates that higher yields of EGT may be attainable through further modification of S. 
cerevisiae and EgtA by genetic manipulation. 
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4.2 Future Work 
 Now that recombinant expression of EgtA in S. cerevisiae has been confirmed to 
produce EGT a continuous fermentation should be conducted using the EGT producing S. 
cerevisiae strain to determine how large a quantity of EGT can be produced. The conditions 
for fermentation should also be optimized such as pH, temperature and fermentation time. 
Media conditions should also be optimized including nitrogen source, carbon source and 
investigate the supplementation of media with histidine and or cysteine the precursor amino 
acids to EGT. Other vectors may be looked but referring to the literature has indicated that 
the GPD promoter and 2µ origin of replication used in the plasmid p426 GPD to express EGT 
may be the strongest available (Blazeck et al., 2012; Romanos et al., 1992). The use of 
different yeast strains to express recombinant EgtA should be investigated to see if this can 
increase EGT production. 
An in vivo study could be carried out using purified histidine tagged EgtA and either 
Egt2a or native yeast Nfs1 to confirm their role in the production of EGT. A similar study 
was used by Seebeck, (2010) to confirm the role of the 5 gene EGT cluster in the mycobacteria 
(Vit et al., 2015). A study such as this could also be used investigate whether EgtA requires 
the same co-factors FeSO4 and SAM. Further work should also be carried out in understanding 
the role Egt2a plays in EGT production in A. fumigatus perhaps by creating an overexpression 
mutant and a Δegt2a mutant.  
In A. fumigatus other sulphur containing metabolites could be studied to identify 
whether Egt2A and Nfs1 play a role in there synthesis. In S. cerevisiae strains producing EGT, 
the levels of GSH should be checked to observe whether EGT biosynthesis is interfering with 
GSH biosynthetic machinery. 
  The intermediates produced by EgtA in the EGT biosynthetic process have not yet 
been identified partly due to the labelling technique used to identify EGT is not suitable for 
their identification. To detect intermediates normal phase-HPLC analysis should be 
considered as well as perhaps using other labelling techniques targeting the quaternary amine 
group present on all of the intermediates known intermediates. This could be carried out by 
perhaps using dansyl chloride which has been seen to label primary, secondary and tertiary 
amine groups. Dansylated derivatives have also been shown to be detectable using a Zorbax 
Eclipse XDB C18 as used in this study (Bartzatt, 2001; Meseguer Lloret et al., 2004; Onal, 
2007). The Egt-1 overexpression mutant in S. pombe was identified to produce selenoneine 
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when fed Na2SeO4 (Pluskal et al., 2014). This should be investigated in the S. cerevisiae 
producing EGT strain as this relatively unknown compound may also have potential 
nutraceutical activity. However an alternative means will be needed to detect selenoneine as 
alkylation by 5’-IAF would be unsuitable however normal phase-HPLC would be ideal. In 
conclusion, the scene is now set for future studies to explore the biosynthesis, and exploit the 
potential, of EGT production by S. cerevisiae. 
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Appendices 
 
 
 
 
 
 
 
 
 
 
 
6.1 Appendices 
 
>EGTA cDNA 
 
ATGTCCCCGTTGCCGTGTCCTTCGAAAAAGGTCGAGATTGTCGATATACATCGA
AATGACGTGGAATTCTCGCTCGTGAATGAGATTCGCAAGGGCCTCAACCCTCCC
GAGGGTACTCCAAGATCATTGCCCACCATGCTGCTCTACGACGCTCAAGGGCTT
126 
 
AAGCTCTTCGAGGAGATCACCTACGTGGATGAGTACTACCTGACCAACGCGGAA
ATCGAAGTGTTGCAGAACCACTCCAAGAAGATTGTGGAACGCGTCCCCGAGAA
CGCACAATTATTGGAGCTGGGTAGTGGGAACCTTCGTAAGATCAAGATCCTTCT
TCAAGAGTTCGAGCGGACAGGAAAGCACGTCGACTACTATGCGTTGGATCTATC
CCTGTCAGAGCTACAGCGGACCTTTGTCGAGGTATCATCTGACGAGTACTCTCA
CGTTGATCTCCACGGTCTTCACGGGACCTATGATGATGCCCTTGCCTGGCTGAGC
AATCCCCAGAACCTACAGCGTCCCACTGTGGTTATGTCTATGGGATCCTCAATT
GGGAATTTCAGTCGTGAAGGTGCAGCAGAGTTTCTTGCCCAATTTGCTCGGCTG
CTCAAGCCATCCGATCTGATGATCATTGGGCTAGATGCTTGTACAGACCCGGAC
AAGGTCTACAAGGCATACAACGATTCAAAGGGCATTACTCAGAGGTTCTACGA
GAATGGGCTATTACATGCGAATGCAGTCCTTGGATACGAGGCATTCCAACTTTC
GGAATGGGAGGTGGTGACAGACTACGACGTTGCCGGGGGCCGACATCGAGCAT
TCTACTCACCGAAGCAGAATGTTACAATCGATGGCGTGCTTCTGCAAAAAGGCG
AGAAATTGGTTTTTGAAGAGGCAACAAAGTATAGCCCTCAACAACGGGAGCAA
CTCTGGCGGGATGCAAACCTCGTCCTTTGTGAGGAGCTTGGAATTAGCTCTGAG
GAATACCATATCCATCTGCTGTCACCGCCAACCCTCAGCCTTCCCAGTCAACCG
TCCGAATATGCTGCCAATCCAGTTCCGAGCTTCAAAGAATTCCAGTCATTGTGG
ACCGCTTGGGACACTGTGACAAAGGCCATGGTGCCCCGCGAAGAACTCCTCGC
GAAACCTATCAAGCTTCGCAATGCATTGATCTTCTACTTTGGACACATCCCCACA
TTCACGGACATCCACTTGACACGGGCTCTTGGTGGCTCTCCAACAGAACCACGA
AACTATCGACAGATTTTCGAGCGTGGGATTGACCCCGACGTAGACAATCCCGAG
CACTGTCACTCCCATAGTGAGATTCCGGATGAATGGCCTCCCCTTGCTGAGATA
CTGGATTATCAGGATAGAGTCAGAAGTAGGGTTGATTCGGTTTTGCAGAGGGAT
GACATAACACAGAACCGCTGCCTGGGGGAAGCACTCTGGATTGGCTTCGAACA
CGAAGCGATGCACCTAGAGACCTTTCTCTATATGCTTTTGCAGAGTGACAAGAC
CCTCCCACCGCCCCTTGCAGACAGACCAGATTTTGAGAAGTTGTTCCATCAGGC
CAGAGCGAACGCGAAACCAAATGAATGGTTTGCTATACCAGAACAGACATTAT
CCATCGGTTTTGACGATACTGACGAACAATCTTTGCCTGATGTGTCTTTTGGATG
GGACAATGAGAAGCCTCAGCGAACGATCACAGTTCGTGCTTTCGAAGCACAGG
CTCATGCTATAACAAACGGCGAATATGCCAAATATCTGCAAGCGACTCGTCAGC
GCCGGCGGCCAGAGTCGTGGGTTCTAACTCATTCGGATGAGAATTATCCAATCT
CCAAGGGGGTGACTCTGGAGAGCAGCCAAGCCACAAAGGATTTCATGGACAAC
TTCGCTGTCCGCACCGTCTTTGGACCTGTTCCGCTTGAATTCGCGCAGGATTGGC
CTGTTATGGCTTCCTATGACGAACTGGCCCTATACGCCGAATGGGTGGGCTGCA
GACTTCCCACTTATGAGGAGGTCAAGAGTATCTACAACTACTCCGCTCAGCTGA
AGGAGACAAGACAACATGAGCCATCAGATCACGAGAGCAACGGTGTGAAGGGC
ATTAACCGTGATATGGTGACGAACGGGCACTCGAAGGTTCACCAGGATAAGCC
CCGGACCCCAGAACGTCAGCCAATCCAACCTCCTTCCCAAAGCACAATGCCAGT
ATTTGTTGACCTCCACGGTTGCAACGTTGGGTTCAAGCACTGGCACCCTACCCC
GGTCATCCAGAACGGCGATCGACTCGCCGGTCACGGTGAGCTGGGAGGAGTCT
GGGAATGGACCAGCACGCCACTGACGCCACATGATGGCTTCAAGGCCATGGAT
ATTTATCCAGGTTATACAGCGGACTTCTTTGATGGAAAGCACAACATTGTCCTG
GGTGGTTCATGGGCCACGCATCCTAGAATTGCGGGACGGACAACATTCGTCAAC
TGGTATCAGCACAACTATCCTTACACTTGGGCGGGAGCACGTCTCGTGCGCAGC
CAGTAG 
 
 
 
> Egt2a cDNA 
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ATGTCCGCTCCCACACCCTTTGGTGCCTCTATGGCAAAATCTCACTTCATGTTCG
ACCCCGACTTCAAAAACCTCAATCATGGCTCGTTTGGCACATATCCCGTTGCAG
TGCAGACAGCTCTGCGACACTTCCAATCGCAAGTGGAGGCCCGTCCGGATCCGT
TCATCCGGCACATCCAGCCCCAATTGATAGACGAAGCCCGCCGCGCCGTGGCCT
CGCTGCTCAATGTGCCCACCAACGAGTGCGTGTTCGTCAAGAACGCCTCGACGG
GCGTCAACACCGTCCTGCGCAACCTTGTCTTCAAGCAGGGCGATGTGCTGGTGT
ATTTCGACACCGTGTACGGCGCTGTCGAGAAGACCCTTGTCTCGCTGACTGAGA
CCACGCCGCTGCAGCTGCGCAAGGTCCAGTACCAGTTCCCCATTAGCCATGACG
AGCTGGTGCGGAAGTTCCTGGAGGTCGTGGCGAGTGCTACGGCGGAGGGGTTG
ACGGTTCGTGTTGCGGTGTTTGATACGATTGTCAGTTTGCCTGGCGTGCGGTTC 
CCGTTTGAGCGGTTGATCGAGGCGTGTCGCGCCGAGGGGATCTTGAGCGTTGTG
GACGGGGCACATGGGATCGGGCAGATTCCCCTGGATCTGGGTGCTTTGCAGCCG
GATTTCTTCACGACGAATTGTCACAAGTGGCTGTATACCCCCCGCGGCAGCGCC
ATCCTCTACGTCCCCCTTCGCAACCAGCATCTCATCCGGACCACTCTCCCCACTT
CCTGGGGCTTCATCCCATCCCCGGACTCCCCCACCACCGCGCCCTCGCTCATGC
GCAGCAGCGGCTCGGGCAAGTCCGCCTTCGAGGAGCTCTTCGAGTTCGTCGCGA
CCACCGACGACACGGCGTACCTGTGTGTTCCGGCAGCGCTGAAATTCCGCTCCC
AGGTCTGCGGCGGCGAGGACCGCATCTACGCTTACCTGGAGAAGCTGGCGATG
GAGGCCGGGGACATTGTTGCCGCGGCGCTGGGCACGGAGGTGATGCAGGAGCC
CGGCTTGAAGCCCGGAGAGGTCAGTCAGCTGCGCCGCTGTGCCATGGCGACCGT
GCGGCTGCCGTTTGCCGTGTCTGGTAGTGAGCAGGATCCGAAGACGGCCTCGGC
TCGATTGACGCTGCAGGCTGCGCAGGCCGCGGAGGTTGCTGGGGAGATCCAGA
AGGCGTTGGTGCGGGACTATGGGACCTTTGTGCCTGTGTTTGCGCACGGCGGGT
GGTTGTGGACCCGGCTGAGTGCGCAGGTTTACTTGGAGAAGAGCGATTTCGAGT
GGCTTGCAGGTGTGCTGAACGAGCTATGCAACAAGCTGGTGAAGAAGTTTGCCG
AGCCAAAGTTGTGA 
 
 
 
 
 
 
 
> Egt2b cDNA 
 
ATGTCTAGCGTTACGCCATCTGTCTTGAGACAGGCATCTCGTGCCTATGCTCGTC
GACTTTCGTCGACCCAGCATGGCTCCCTGGCGACCGCGTCCTTCCCCAGACGGG
CGCTCGCCACATCCAGTGGTGCAGCTTCGAGACGGACATATGTTACCGAAACCA
AAGCTGGAAACGCTCAGGTTTCGATCGACACAGCCATCAAACAGGAGCAGAAG
AACTTCATCAAGCAGACAGGTCTTGAGCCTGGAAAGGTTGAACTTCCTGCCTCT
GGCATCTCCGGAGATGCTTCAATGAGTCCCTCTGCGGGTATTTTGAAACAAGCA
128 
 
ACTGTTATGGATCAGGGAACACGGCCTATTTATTTGGATATGCAGGCCACTACG
CCGGTTGATCCTCGTGTTCTCGATGCTATGCTTCCCTATCTCACCGGTATCTACG
GAAACCCGCATTCCAGGACTCACGCATATGGTTGGGAGTCGGAGAAGGCTGTC
GAACAAGCCAGAGAATATATTGCGAAATTGATTGGGGCGGATCCAAAGGAAAT
CATCTTTACGAGTGGCGCCACCGAAAGTAACAACATGAGCATCAAGGGTGTGG
CCAGATTCTTTGGTCGTTCCGGCAAGAAGAAGCACATTATCACATCGCAGACTG
AGCACAAGTGTGTCTTGGACAGCTGCCGGCATCTTCAAGATGAGGGATTCGAAG
TCACATATTTGCCCGTTCAAAATAACGGATTGATCCGGATGGAGGATCTCGAGG
CGGCCATTCGACCCGACACGGCTCTAGTCAGCATCATGGCTGTCAACAATGAGA
TTGGTGTTATTCAACCCTTGGAAGAGATCGGAAAGCTCTGCCGTGCGAAGAAGG
TTTTCTTCCACACTGATGCTGCTCAGGCAGTTGGCAAGATCCCCTTGGATGTCAA
CAAGCTGAACATCGATTTGATGTCTATCTCCAGCCACAAGATTTATGGGCCCAA
GGGTATTGGTGCTTGCTATGTTCGACGCAGACCCAGGGTTCGCCTTGAGCCCAT
CATCTCCGGTGGTGGACAGGAACGAGGATTGCGCAGTGGCACGCTCGCTCCTCA
CCTGGTTGTTGGTTTCGGTGAGGCTTGCCGCATCGCCAGTCAGGACATGGAGTA
TGATAGGAAGCACGTTGAGCGGCTGTCGAAGCGTCTGCTGGATGGACTTCTGGC
GATGGAACACACCACGCTCAATGGGGATGCTGAGCGCCATTACCCTGGATGCGT
CAACGTCTCGTTCGCTTATATTGAGGGCGAGTCTCTTCTGATGGCTCTGAAGGAC
ATTGCATTGTCGTCTGGTAGTGCCTGTACCTCTGCCTCGCTGGAACCCAGCTACG
TCCTTCGAGCATTGGGCAGCAGCGACGAGAGCGCTCACAGCAGCATTCGTTTTG
GCATTGGACGGTTCACAACAGATAGCGAGATTGACTACGTCCTCAAGGCTGTTC
AAGACCGTGTCCATTTCCTCCGAGAGCTGAGTCCTCTGTGGGAGCTGGTCCAGG
AGGGCATTGATCTAAACACCATCCAATGGAGTCAGCATTAG 
 
 
 
 
 
 
 
 
 
 
>EgtA Protein Sequence  
MSPLPCPSKKVEIVDIHRNDVEFSLVNEIRKGLNPPEGTPRSLPTMLLYDAQGLKLFE
EITYVDEYYLTNAEIEVLQNHSKKIVERVPENAQLLELGSGNLRKIKILLQEFERTGK
HVDYYALDLSLSELQRTFVEVSSDEYSHVDLHGLHGTYDDALAWLSNPQNLQRPT
VVMSMGSSIGNFSREGAAEFLAQFARLLKPSDLMIIGLDACTDPDKVYKAYNDSKG
ITQRFYENGLLHANAVLGYEAFQLSEWEVVTDYDVAGGRHRAFYSPKQNVTIDGV
LLQKGEKLVFEEATKYSPQQREQLWRDANLVLCEELGISSEEYHIHLLSPPTLSLPSQ
129 
 
PSEYAANPVPSFKEFQSLWTAWDTVTKAMVPREELLAKPIKLRNALIFYFGHIPTFT
DIHLTRALGGSPTEPRNYRQIFERGIDPDVDNPEHCHSHSEIPDEWPPLAEILDYQDR
VRSRVDSVLQRDDITQNRCLGEALWIGFEHEAMHLETFLYMLLQSDKTLPPPLADR
PDFEKLFHQARANAKPNEWFAIPEQTLSIGFDDTDEQSLPDVSFGWDNEKPQRTITV
RAFEAQAHAITNGEYAKYLQATRQRRRPESWVLTHSDENYPISKGVTLESSQATKD
FMDNFAVRTVFGPVPLEFAQDWPVMASYDELALYAEWVGCRLPTYEEVKSIYNYS
AQLKETRQHEPSDHESNGVKGINRDMVTNGHSKVHQDKPRTPERQPIQPPSQSTMP
VFVDLHGCNVGFKHWHPTPVIQNGDRLAGHGELGGVWEWTSTPLTPHDGFKAMD
IYPGYTADFFDGKHNIVLGGSWATHPRIAGRTTFVNWYQHNYPYTWAGARLVRSQ
* 
 
 
>Egt2a Protein Sequence  
MSAPTPFGASMAKSHFMFDPDFKNLNHGSFGTYPVAVQTALRHFQSQVEARPDPFI
RHIQPQLIDEARRAVASLLNVPTNECVFVKNASTGVNTVLRNLVFKQGDVLVYFDT
VYGAVEKTLVSLTETTPLQLRKVQYQFPISHDELVRKFLEVVASATAEGLTVRVAV
FDTIVSLPGVRFPFERLIEACRAEGILSVVDGAHGIGQIPLDLGALQPDFFTTNCHKW
LYTPRGSAILYVPLRNQHLIRTTLPTSWGFIPSPDSPTTAPSLMRSSGSGKSAFEELFE
FVATTDDTAYLCVPAALKFRSQVCGGEDRIYAYLEKLAMEAGDIVAAALGTEVMQ
EPGLKPGEVSQLRRCAMATVRLPFAVSGSEQDPKTASARLTLQAAQAAEVAGEIQK
ALVRDYGTFVPVFAHGGWLWTRLSAQVYLEKSDFEWLAGVLNELCNKLVKKFAE
PKL* 
 
> Egt2b Protein Sequence  
MSSVTPSVLRQASRAYARRLSSTQHGSLATASFPRRALATSSGAASRRTYVTETKA
GNAQVSIDTAIKQEQKNFIKQTGLEPGKVELPASGISGDASMSPSAGILKQATVMDQ
GTRPIYLDMQATTPVDPRVLDAMLPYLTGIYGNPHSRTHAYGWESEKAVEQAREYI
AKLIGADPKEIIFTSGATESNNMSIKGVARFFGRSGKKKHIITSQTEHKCVLDSCRHL
QDEGFEVTYLPVQNNGLIRMEDLEAAIRPDTALVSIMAVNNEIGVIQPLEEIGKLCR
AKKVFFHTDAAQAVGKIPLDVNKLNIDLMSISSHKIYGPKGIGACYVRRRPRVRLEP
IISGGGQERGLRSGTLAPHLVVGFGEACRIASQDMEYDRKHVERLSKRLLDGLLAM
EHTTLNGDAERHYPGCVNVSFAYIEGESLLMALKDIALSSGSACTSASLEPSYVLRA
LGSSDESAHSSIRFGIGRFTTDSEIDYVLKAVQDRVHFLRELSPLWELVQEGIDLNTI
QWSQH* 
